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CHAPTER I
INTRODUCTION
Effectiveness of depression treatment varies considerably among individuals. This is
not surprising given the complexity and heterogeneity of depression. For instance,
common presentations of depression include symptoms ranging from psychomotor
retardation to high levels of restlessness and agitation. Yet, it remains challenging to
effectively and efficiently predict what treatment will work best for which patient.
Certain symptoms and symptom clusters (i.e. symptoms which tend to co-occur) have
shown predictive value in the past. For instance, depression involving significant anxiety
symptoms such as worry or physiological arousal symptoms may require different
treatment than depression without those features (e.g., Fawcett, 1997; Grunhaus, Harel,
Krugler, Pande & Haskett, 1988). There is evidence that the melancholic depression
subtype – i.e. the cluster of symptoms including flat affect, anhedonia, psychomotor
retardation, lack of appetite, etc. – responds better to a tricyclic antidepressants than to
monoamine oxidase inhibitors (MAOIs) or selective serotonin reuptake inhibitors
(SSRIs) (e.g., Danish University Antidepressant Group, 1986; Roose, Glassman, Attia &
Woodring, 1994; Perry, 1996), while the atypical subtype – including symptoms such as
mood reactivity, increased appetite, etc. – shows the reverse pattern (e.g., Pande, Birkett,
Fechner-Bates, Haskett & Greden, 1996; Quitkin, Stewart, McGrath, Tricamo, Rabkin et
al., 1993). Previous research in this area involved mainly pharmacological studies and
there have been significant inconsistencies in findings among these trials. Many
questions remain regarding the potential of depression symptom clusters as predictors of
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treatment response. Additionally, prior research in this area has not always been guided
by theoretical models.
In the present study, the tripartite model (Clark & Watson, 1991) will be used as a
framework for investigating depression symptom clusters as predictors of treatment
response. The tripartite model categorizes symptoms of anxiety and depression into
those unique to each phenomenon versus those shared by both.
Negative Affect (NA) and Positive Affect (PA)
The constructs of Negative Affect (NA) and Positive Affect (PA) play a central role
in the tripartite model. These constructs will therefore be introduced and their relation to
anxiety and depression addressed, before focusing in more detail on the tripartite model
symptom clusters. Unlike the term emotion, which often refers to a complex and
multimodal construct with subjective, physiological and expressive/behavioral
components, the term affect is commonly used to denote subjectively experienced
feelings (Watson & Vaidya, 2003). This study will focus on state affect, which refers to
a transient episode of experienced feelings and is distinguished from trait affect, which
refers to stable individual differences in experienced feelings (Watson & Vaidya).
There are a number of dimensional and discrete models of the structure of affect (e.g.,
see Feldman Barrett & Russell,1998; Keltner & Ekman, 2000; Watson & Tellegen, 1985;
Watson & Vaidya, 2003). As Watson and Vaidya (2003) point out, these do not have to
be mutually exclusive, but may reflect different levels of specificity in the description of
affect. In the context of this study, however, affect will be approached exclusively from a
dimensional perspective. Research on affect involving self-reports, facial and/or vocal
expression of emotion, and semantic differential ratings of affect words, most strongly
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support a two-factor structure of affect (see Watson & Vaidya, 2003; Watson & Tellegen,
1985).
In the past, researchers have emphasized the two dimensions of Pleasantness (i.e.
valence) and Activation (i.e. arousal) as being core to the description of affect. Larsen
and Diener (1992), for example, proposed that the two bipolar dimensions Pleasantness
(pleasant versus unpleasant) and Activation (high versus low activation) are orthogonal
and define a space in which affect terms can be placed based on their degree of
pleasantness and activation. As can be seen in Figure 1, NA and PA are basically another
conceptualization of the same affect space (e.g., Larsen & Diener, 1992; Watson &
Tellegen, 1985; Watson, Wiese, Vaidya & Tellegen, 1999). In the two-factor affective
model by Watson and Tellegen (Tellegen, 1985; Watson & Tellegen, 1985), these two
bipolar axes represent the two basic dimensions of affect.
High PA
elated
enthusiastic
excited
High NA
distressed
jittery
nervous
Low NA
at rest
calm
relaxed
Low PA
dull
sluggish
drowsy
Low Activation
High Activation
PleasantUnpleasant
Figure 1. Two-Factor Structure of Self-Reported Affect (adapted from Watson &Tellegen, 1985)
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Although the labels Negative Affect and Positive Affect appear to refer to valence
only, NA and PA are described in terms of both valence and arousal (see Figure 1). High
NA and high PA, for example, share a component of high activation, but are of opposite
valence. According to Watson, Clark and Carey (1988), high NA "is a general factor of
subjective distress, and subsumes a broad range of negative mood states, including fear,
anxiety, hostility, scorn, and disgust" (p.347). Low NA is the absence of negative
activation (i.e. a state of relaxation and calmness). PA refers to "one's level of
pleasurable engagement with the environment" (Watson et al., p.347). A state of high PA
can be described as enthusiastic, energetic and interested, whereas low PA would refer to
a state of fatigue and lethargy.
It should be noted that the schema presented in Figure 1 is used for illustration
purposes and that implications regarding the structure of affect need to be treated with
caution. PA and NA, for example, are depicted as 45 º rotated from the Activation and
Pleasantness axes, which technically implies a set of specific correlations between the
axes. Instead, however, there is some evidence for significant deviation from the
correlations expected from this model. Activation, for example, may be more closely
related to high PA than to high NA (Watson, Wiese, Vaidya & Tellegen, 1999). More
importantly, high PA and high NA, which according to this model are expected to be
uncorrelated, have been shown consistently to be moderately negatively correlated (e.g.,
Brown, Chorpita & Barlow, 1998; Feldman Barrett & Russell, 1998; Tellegen, Watson &
Clark, 1999; for a discussion of the structural properties of affect, see Watson et al.,
1999).
One of the most commonly used measures of PA and NA, which was also used in the
present study, is the Positive and Negative Affect Scale (PANAS), a 20-item self-report
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measure developed by Watson, Clark and Tellegen (1988). The PANAS is based on the
2-factor affect model and contains two scales assessing high PA and high NA (see
Table 1 for a list of the items). Different versions of the PANAS have been created in
order to address different time frames. In the "current" version, participants are asked
how they currently feel and in the "week" version, participants are asked how they felt
over the past week. In the “trait” version, participants are asked how they feel in general.
Trait NA refers to an individual's stable disposition to experience aversive mood states
including anger, fear and guilt; trait PA refers to an individual's stable tendency to
experience such states as cheerfulness and enthusiasm.
NA and PA in Depression
There is strong support for the notion that depression involves a combination of high
NA and low PA (e.g., Brown et al., 1998; Clark & Watson, 1991; Clark, Watson &
Mineka, 1994; Tellegen, 1985; Watson, Clark & Carey, 1988). Although some of the
studies (e.g., Brown et al., 1998; Watson, Clark & Carey, 1988) have used trait rather
than state measures of NA and PA, results still argue for the involvement of high state
NA and low state PA in depression as the affect states have been shown to be
significantly correlated with their trait equivalents (Watson, Clark & Tellegen, 1988).
Watson, Clark and Carey (1988), for instance, tested the association of trait NA and
PA (assessed by the Multidimensional Personality Questionnaire; Tellegen, 1982) with
anxiety and depression symptoms and diagnoses. Their sample included 150 inpatients
and outpatients diagnosed with at least one anxiety (social phobia, simple phobia,
obsessive compulsive disorder, or panic/agoraphobia) or depression disorder (major
depression or dysthymia) according to the Diagnostic and Statistical Manual of Mental
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Disorders, third edition (DSM-III; American Psychiatric Association [APA], 1980).
They found that high trait NA was related to a wide range of individual anxiety and
depression symptoms. High trait NA was also related to the severity of anxiety
symptoms (correlation coefficients ranged from .25 to .37 depending on the category of
anxiety symptoms) and severity of depression symptoms (.57). Low trait PA, on the
other hand, was more consistently related to depression symptoms than to anxiety
symptoms, and it had a stronger association with depression symptom severity (-.40) than
with anxiety symptom severity (all indices smaller than -.16). Watson and colleagues
concluded that high trait NA may be common to both anxiety and depression, while low
trait PA may be specific to depression.
The Tripartite Model
Based on these and other research findings, the tripartite model (e.g. Clark & Watson,
1991) posits that NA is shared by anxiety and depression and low PA is specific to
depression. This model expands these two affect components by including other non-
affective symptoms, and adding a third component, which represents symptoms specific
to anxiety.
According to Watson, Clark and colleagues (e.g. Clark & Watson 1991, Watson et
al., 1995a) symptoms shared by anxiety and depression disorders include symptoms
associated with high NA such as nervousness or being upset, and other general distress
symptoms such as difficulty concentrating. Symptoms specific to depression include
those associated with low PA such as the absence of liveliness and the lack of enthusiasm
and interest. The anxiety-specific cluster contains somatic anxiety symptoms such as
tachycardia, sweating, or muscle tension.
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The tripartite model structure is in large parts based on factor analytic work,
particularly by Watson, Clark, and colleagues. Watson and colleagues (Watson et al.,
1995a, b) have explored the factor structure of anxiety and depression symptoms across
five samples including patient and non-patient participants. Factor analysis on 90
symptoms associated with depression and/or anxiety supported a three-factor solution
highly consistent with the tripartite model. The first factor included symptoms of general
distress and high NA (hereafter referred to as GD), the second factor contained symptoms
of anhedonia and low PA (hereafter referred to as ANH) and the third factor consisted of
symptoms of somatic anxiety (hereafter referred to as SA) (Watson et al., 1995a). It
should be noted, however, that not all of the factor analytic findings were entirely
consistent with the model. Most notably, several items reflecting loss of interest such as
"felt bored" and "took extra effort to get started" which are conceptually more consistent
with the ANH dimension, actually loaded higher on the GD dimension.
It is also noteworthy that these factors are not expected to be strictly independent.
Studies involving the PANAS in clinical (e.g., Brown et al., 1998) and non-clinical
populations (e.g., Feldman Barrett & Russell, 1998; Tellegen, Watson et al., 1999,
Watson et al., 1995b) have found moderate negative correlations between NA and PA
(ranging from -.36 to -.46). Factor-analytic studies on the tripartite model structure
involving both clinical and non-clinical populations greatly varied with regard to reported
correlations between the factors. Correlations were all positive and coefficients varied
from (a) moderate to high for GD/NA versus ANH (ranging from .49 to .84),
(b) moderate to high for GD/NA versus SA (ranging from .50 to .72) and (c) low to high
for SA versus ANH (ranging from .23 to .72) (Brown et al., 1998; Joiner, 1996; Joiner,
Steer, Beck, Schmidt, Rudd & Catanzaro, 1999; Lambert et al., 2004; Watson et al.,
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1995b). Sample characteristics as well as statistical methods appear to play a major role
in the variability between studies in this respect. For example, higher levels of pathology
tended to be associated with higher correlations between the symptom components.
It is important to note that the tripartite model represents one of many possible ways
to define separable symptom dimensions of depression and anxiety. In order to evaluate
the validity of the tripartite model, the goodness-of-fit of this model must be tested
against the goodness-of-fit of alternative models. Recently, there has been a growing
interest in this topic and several empirical studies have attempted to explore the validity
of the tripartite model structure, across a variety of populations. Most studies provide at
least some support for the tripartite structure over other factor models in a variety of adult
outpatient samples (e.g., Clark, Steer & Beck, 1994; Joiner, 1996; Joiner, Catanzaro &
Laurent, 1996; Marshall, Sherbourne, Meredith, Camp & Hays, 2003; Steer, Clark, Beck
& Raniery, 1995), in older adult outpatients (Cook, Orvaschel, Simco, Hersen & Joiner,
2004), and in children / adolescent samples (Chorpita, B., 2002; Jacques & Mash, 2003;
Lambert, McCreary, Joiner, Schmidt & Ialongo, 2004; Turner & Barrett, 2003).
Relatively few studies have provided direct evidence against the three-factor
structure. Burns & Eidelson (1998) analyzed data obtained from a mixed outpatient
sample (N = 483). For their analyses, they selected items from the Beck Depression
Inventory (BDI; Beck & Steer, 1987), the Burns Anxiety Inventory (Burns, 1989), and
the Symptom Checklist–90 (Derogatis, Rickels, & Rock, 1976). Using structural
equation modeling, the authors directly compared two models with the three-factor
structure of the tripartite model (with factors anhedonia, negative affect, and somatic
anxiety). The first model was a four-factor model with the factors anhedonia, somatic
anxiety, non-specific depression, and non-specific anxiety. The second model was a
9
second-order factor model with the four factors from the previous model serving as first-
order factors and two additional factors serving as second-order factors. One of these
second-order factors, named depression, represented shared variance of the factors
anhedonia and non-specific depression; the other, named anxiety, represented the shared
variance of the factors somatic anxiety and non-specific anxiety. The authors found both
of these models to be significantly superior to the three-factor model.
An exploratory factor-analytic study by Riskind, Beck, Brown, and Steer (1987)
involving the Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) and the
Hamilton Rating Scale for Anxiety (HRSA; Hamilton, 1959). The authors derived a two-
factor structure, reflecting depression and anxiety, and found that several items from the
HRSD loaded higher on the anxiety factor than on the depression factor and some HRSA
items showed the opposite pattern. Unfortunately, this two-factor model was not
compared to alternative models. Further, utilizing the BDI and the Beck Anxiety
Inventory (BAI; Beck & Steer, 1990), Enns, Cox, Parker and Guertin (1998) found a two-
factor model to better represent their data than a one-factor model. They did not,
however, consider a three-factor model. In sum, when the tripartite model structure was
directly tested against other factor structures, it was most often found superior to other
models.
When including exploratory factor analyses performed on individual symptom
measures, there have been significant inconsistencies with regard to the number and kind
of symptom dimensions found to best describe depression alone (for reviews, see Beck,
Steer & Garbin, 1988; Clark & Watson, 1991; Mandell, 1987). In her review of factor-
analytic studies involving the HRSD, Mandell (1987) concluded that no consistent factor
pattern can be identified among the different studies. In studies published since this
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review, most frequently the four-factor solution was found superior to other factor
solutions (e.g., Dozois, 2003; O’Brien & Glaudin, 1988; Onega & Abraham, 1997;
Pancheri, Picardi, Pasquini, Gaetano, & Biondi, 2002); however, best fitting models were
reported to have as few as one and as many as six factors (e.g., Amin, Daradkeh, Hamdi,
& Abou-Saleh, 1999; Fleck, Poirier-Littre, Guelfi, Bourdel, et. al., 1995; Maier, Phillipp,
Gerken, 1986; Marcos & Salamero, 1990). Despite this great variation in reported factor
structures for the HRSD, however, almost all reports identified one factor representing
clinical ratings of pure depression symptoms (e.g., guilt, lack of interest/activity,
retardation, and depressed mood) and (at least) one different factor representing anxiety
and somatic complaints. Also frequently reported were two factors representing
insomnia and anorexia, respectively.
Reports on the factor structure of the BDI and its upgraded version, the BDI-II (Beck,
Steer, & Brown, 1996), which more adequately reflects the DSM –IV criteria for Major
Depressive Disorder (APA, 1994), are more consistent than those regarding the HRSD
(Mandell, 1987). Most findings included two factors that can be described as self-
reported negative cognition and affective/motivational problems, which bear a strong
resemblance to the tripartite model dimensions of GD and ANH, respectively. However,
some studies found that these two factors alone best describe the structure of the BDI
(e.g., Beck, Steer, & Brown, 1996; Steer, Ball, Ranieri, & Beck, 1999), whereas others
identified a third factor reflecting somatic complaints (e.g., Beck & Beamesderfer, 1974;
Burne & Baron, 1993; Clark, Cavanaugh, & Gibbons, 1983; Steer, Beck, Riskind, &
Brown, 1987; Tanaka & Hubs, 1984).
Variation in results are likely, at least in part, attributable to measurement
characteristics (e.g., selection of items, response format), sample characteristics (e.g.,
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base rate of symptoms), and/or the choice and implementation of statistical procedures
(Beck, Steer & Garbin, 1988). The number of extracted factors varies with statistical
procedures as well as the criterion for factor extraction used by the investigator. In sum,
exploratory factor-analytic studies on some individual depression measures revealed
factors which in some ways resemble the tripartite model dimensions of GD and ANH;
yet, findings are inconsistent.
Further support for the tripartite model stems from psychophysiological,
neurobiological and pharmacological studies which suggest that distinct (but interactive)
biological systems underlie the different symptom dimensions. The basic distinction that
has consistently emerged is between an aversive and an appetitive motivation system
(e.g., Carver & White, 1994; Clark, Watson & Mineka, 1994; Fowles, 1988, 1994; Gray,
1982; Lang, Bradley & Cuthbert, 1998; Watson et al., 1999). NA has been linked to the
aversive system which is normally activated when threat is anticipated. Behaviorally,
this leads to a defensive reaction such as inhibition or passive avoidance of some activity
(e.g., Gray, 1982; Lang et al., 1998; Lang, Davis & Öhman, 2000). SA may also be
produced by an aversive motivation system (Lang et al., 1998, 2000; Shelton &
Tomarken, 2001), but – different from NA – has been linked to a bodily fear response to
perceived acute threat, which may serve the biological function of preparing the body for
immediate action (e.g., Gray 1982; Barlow, 1988). PA and anhedonia have been linked
to an appetitive system responsible for interest, curiosity and the approach of rewarding
stimuli (Dichter, 2001). For a more comprehensive review of this literature, the reader is
referred to Mineka, Watson, and Clark (1998).
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Application of the Tripartite Model to Measurement
One of the most crucial functions of depression assessment is to assign and evaluate
treatment strategies. In order to optimize treatment of this highly complex and
heterogeneous disorder, it is essential to adequately assess all features of depression
which may inform treatment.
While many traditional self-report and clinician-rated depression measures show high
convergent validity (i.e. assess a common depression syndrome), poor discriminate
validity between anxiety and depression measures has been reported consistently and
across healthy and patient populations (Watson et al., 1995b). In a review of studies
using a variety of depression and anxiety symptom measures, Clark and Watson (1991)
found good convergent validity among depression self-report ratings with correlation
coefficients in the low .70's. However, average discriminant correlation coefficients
(within and across instruments) were almost as high, ranging from .62 to .70. It is
interesting to note that clinician ratings, while assessing a consistent construct of
depression with convergent correlation coefficients in the low .80's, show much smaller
discriminant correlations with coefficients ranging from .40 to .45. Although this implies
much better differentiation between depression and anxiety than found in self-report
measures, it still represents significant correlations between anxiety and depression
measures.
Clark and Watson (1991) attribute these high correlations between depression and
anxiety measures to an overrepresentation of shared symptoms (relative to syndrome-
specific symptoms) on both anxiety and depression scales. Also, item overlap between
scales often artificially inflates correlations between the measures. For instance, one of
the most widely used clinician-rating scales for the severity of depression, the HRSD,
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contains six items (depressed mood, early insomnia, middle insomnia, agitation, feelings
of anxiety, and somatic anxiety) which are virtually identical to items on the HRSA. In
general, it appears that despite the fact that anhedonia is a core feature of depression, as
defined by the DSM-IV, it is underrepresented compared to non-specific symptoms at
least in some depression measures (e.g., Dichter, 2001; Feldman, 1993).
The first measure to separately assess the constructs, GD, ANH and SA, is the Mood
and Anxiety Symptom Questionnaire (MASQ; Watson et al., 1995a, b). The MASQ was
created in the attempt to improve discriminant validity between depression and anxiety
and is based conceptually on the tripartite model. It is a 90-item self-report measure on
which subjects rate the extent to which they experienced a list of symptoms associated
with depression and anxiety during the previous week. The measure contains six scales,
three of which are aimed at assessing various facets of GD (GD - Mixed Symptoms, GD -
Depressive Symptoms, and GD - Anxious Symptoms). Two scales, Loss of
Interest/Anhedonia and High Positive Affect assess a dimension ranging from low
positive affect (i.e. anhedonia) to high positive affect, respectively; and finally, the scale
Anxious Arousal is used to assess the construct SA. Although some refinements of the
MASQ may be necessary, the MASQ is superior to traditional depression measures in its
comprehensive assessment of ANH and separate assessment of different symptom
components of depression and anxiety.
Relating the Tripartite Symptom Dimensions to Anxiety and Depression
A core prediction of the tripartite model is that symptoms of the specific clusters,
ANH and SA, can better differentiate between anxiety and depression disorders than
symptoms of the non-specific cluster GD. In their analyses of five samples (three college
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student, one healthy adult, one substance abuse patient, total N = 1883), Watson and
colleagues found support for this prediction (Watson et al., 1995b). The authors created
two sets of scales assessing anxiety- and depression-related symptoms experienced over a
one-week period. One anxiety and one depression scale were based on relatively specific
symptoms; the other scales (one for anxiety and one for depression) were based on non-
specific symptoms. Across all five samples, the correlations between the two scales
consisting of specific symptoms, SA and ANH/PA, were much lower (ranging from .25
to .49) than those between the scales using the non-specific symptoms (ranging from .61
to .78). As the authors point out, on average, the SA and ANH/PA scales shared only
12% of their variance as compared to the 48% variance shared between the non-specific
anxiety and depression scales. These results provide strong support for the prediction
that scales emphasizing SA and ANH/PA better discriminate anxiety from depression
than those emphasizing GD. It is especially noteworthy that the SA and ANH/PA scales
improved discriminant validity while retaining good convergent validity (as indicated by
at least moderate correlations with other standard measures of anxiety and depression,
respectively) (Watson et al., 1995b). This suggests that the SA and ANH/PA scales also
validly assess the constructs of anxiety and depression.
In a related study, Brown and colleagues (1998) tested the structure of the tripartite
model in relation to anxiety and depression disorders (N = 350 outpatients) diagnosed
according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition
(DSM-IV, APA, 1994). They assessed trait NA and PA with the trait version of the
PANAS. In their hierarchical structural model, they found that trait NA was significantly
associated with depression (.67) and with all included anxiety disorders, namely
generalized anxiety disorder (GAD) (.74), panic/agoraphobia (.65), obsessive compulsive
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disorder (OCD) (.43), and social phobia (.31). Trait PA, on the other hand, was
significantly (inversely) related only to depression (-.29) and social anxiety (-.28). The
inverse relation between PA and social phobia, though inconsistent with predictions of
the tripartite model, provides further support the notion that PA is associated with social
engagement, which was suggested, for example, by Clark, Watson and Mineka (1994).
SA symptoms were very strongly associated with panic/agoraphobia (.67), but none of
the other disorders.
Although these findings largely support the relation of the tripartite dimensions to the
diagnostic categories of depression and anxiety, some findings diverge from the
predictions of this model. The extensive variation among anxiety disorders regarding
their associations with NA and SA may be particularly relevant in this context. SA, for
example, proposed by the tripartite model to be specific to anxiety in general, was very
strongly associated with panic/agoraphobia, but was not significantly associated with any
other anxiety disorder included in the study. In fact (after controlling for the variance
explained by NA), SA was slightly negatively associated with GAD (-.22).
Despite the above cited evidence that SA is relative specific to (at least some forms
of) anxiety, given the high prevalence of comorbid anxiety disorders in depressed
populations (e.g. Alloy, Kelly, Mineka & Clemens, 1990; Clark, 1989; Kessler, Nelson,
McGonagle, Liu, Swartz & Blazer, 1996), there is reason to expect up to moderate levels
of SA symptoms in moderately to severely depressed patients (Joiner, 1996) and
therefore this component will be considered in the present study as well.
In sum, several studies have found support for the notion that GD symptoms are
associated with both anxiety and depression, that ANH symptoms are more specific to
depression, and that SA symptoms are more specific to (at least some types of) anxiety.
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Refinements of the tripartite model appear necessary to account for the diversity of
anxiety disorders and their different relations to depression (e.g., Brown et al., 1998;
Chorpita, 2002; Mineka, Watson and Clark, 1998). Also, variation among subtypes of
depression with regard to their relation to the tripartite model symptom clusters remains
unknown.
Application of the Tripartite Model to Treatment
To the knowledge of the author, no published study has compared the efficacy of
pharmacotherapy to CBT with regard to the symptom dimensions of the tripartite model.
Yet, a variety of indirect sources of evidence is available for both treatment modalities,
which helped inform hypotheses regarding differential treatment effects on separate
symptom dimensions proposed in this study. The following briefly describes some
selected examples.
Pharmacotherapy (PT). The effectiveness of SSRIs in the treatment of depression is
well established, although results are somewhat less consistent for more severe
depression (for reviews, see Hirschfeld, 1999; Thase, 2000; Vaswani, Linda & Ramesh,
2003). Paroxetine, the primary medication used in this study, is the most potent of all
currently available SSRIs (Bourin, Chue, Guillon, 2001). In addition to inhibiting
serotonin reuptake, it also inhibits norepinephrine reuptake to some extent (and more than
other SSRIs). This drug, however, has little affinity for dopaminergic receptors (Bourin
et al., 2001). There is evidence that paroxetine is superior to placebo and comparable to
other currently standard medications in the treatment of clinically depressed outpatients
such as tricyclics and other SSRIs (e.g., Dunbar, Cohn, Fabre, Feighner et al., 1991;
Feighner, J. P. & Boyer, W. F., 1989).
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Despite the established efficacy of PT in the treatment of depression, individuals can
differ immensely in their response to specific medications (Gitlin, 2002). Very little has
been published relating the tripartite model symptom dimensions to the treatment of
depression. One of the first publications linking antidepressants to the tripartite model
symptom dimensions was written by Shelton and Tomarken (2001). The authors
proposed a therapeutic heuristic, which favors the use of serotonergic antidepressants in
the treatment of general distress and high NA, and the use of catecholaminergic agents in
the treatment of anhedonia and low PA. The heuristic is based on findings regarding the
pharmacological properties and treatment effects of these different classes of
antidepressants (for a review, see Shelton & Tomarken, 2001).
Although very few studies have investigated the dimensions of the tripartite model in
depression treatment directly, there is empirical support for the notion that SSRIs
specifically reduce symptoms consistent with GD and SA. For example, Knutson and
colleagues (Knutson, Wolkowitz, Cole, Chan, Moore, Johnson et al., 1998) assessed the
effects of paroxetine versus placebo on NA and PA in 51 healthy individuals. The
authors did not specify the outcome measure, but it is likely that the PANAS was used.
After four weeks, treatment with paroxetine (relative to placebo) was related to a
decrease in NA, but no change in PA. Research also suggests that SSRIs are effective in
the treatment of anxiety disorders including panic disorder, social phobia, GAD, OCD,
and post traumatic stress disorder (PTSD) (for a review see Feighner, 1999, and Vaswani
et al., 2002). In an open-label study involving eight weeks of treatment with the SSRI
sertraline, Boyer and colleagues (Boyer, Tassin, Falissart & Troy, 2000) used selected
items from the Inventory for Depressive Symptomatology (Rush, Gullion, Brasco, Jarrett
& Trivedi, 1996) and the Symptom Checklist-90 (Derogatis, Lipman, Covi, 1973) to
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assess the different symptom clusters. The authors found that, in a sample of 140
depressed outpatients, symptoms of general distress and anxiety changed significantly
faster (during the first week of treatment) than more depression-specific symptoms such
as fatigue and anhedonia. Paroxetine has also been found to be associated with relatively
rapid reduction of anxiety and agitation symptoms consistent with GD and SA in some
depression treatment studies (e.g., Ravindran, Judge, Hunter, & Bray, 1997; Sheehan,
Dunbar & Fuell, 1992). However, SSRIs are expected to vary in their effects on
symptoms of SA such as physiological arousal (Gitlin, 2002).
In comparison, in a recent randomized clinical trial, Tomarken and colleagues
(Tomarken, Dichter, Freid, Addington & Shelton, 2004) tested bupropion SR versus
placebo in the treatment of 19 depressed outpatients. Using the 60-item version of the
MASQ (Watson et al., 1995a) as outcome measure, symptoms were tracked over the
course of twelve weeks. Although all assessed symptom dimensions significantly
improved over the course of treatment, bupropion was superior to placebo only with
regard to reducing symptoms of ANH and some types of GD. Bupropion was not
significantly better than placebo in reducing SA or GD symptoms more typical of
anxiety.
Bodkin and colleagues (Bodkin, Lasser, Wines, Gardner & Baldessarini, 1997) were
the first to directly report the differential effects of SSRIs and bupropion on symptoms of
generalized and specific anxiety versus anhedonia. In their study of 27 cases, symptoms
were assessed by non-standardized clinician ratings. They found SSRIs effectively
reduced anxiety, panic and obsessive/compulsive/ruminative symptoms (consistent with
GD and SA), but did not improve (and, in fact, dampened) energy and motivation
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(consistent with ANH). In contrast, bupropion significantly improved energy and
motivation but did not decrease symptoms of anxiety.
On the other hand, catecholaminergic agents such as bupropion and venlafaxine have
also been found to effectively treat anxiety symptoms and, conversely, SSRIs have also
been found to reduce symptoms consistent with anhedonia. A few direct comparisons of
catecholaminergic versus serotonergic agents yielded no significant differential treatment
effects for either GD (e.g., Dichter, Tomarken, Freid, Addington & Shelton, 2005;
Trivedi, Rush, Bolden-Watson, Houser & Metz, 2001) or ANH (e.g., Dichter et al.,
2005). Authors concluded that the two medications, though acting via different
mechanisms, may both be equally effective in the treatment of both, GD and ANH.
In sum, it is difficult to infer the involvement of specific neurotransmitter systems
using evidence from studies investigating medication effects on specific symptoms.
Neurotransmitter systems are interlinked and affect each other; even highly selective
drugs can have indirect effects on various different systems (Shelton & Tomarken, 2001).
Without ruling out the possible involvement of other neurotransmitter systems, Shelton
and Tomarken (2001) nevertheless propose that serotonergic agents (e.g., SSRIs) may
more directly modulate symptoms of general distress and somatic anxiety, while
antidepressants that more strongly target catecholamines (e.g., bupropion) may more
effectively reduce anhedonia and improve appetitive motivation. Although
neurobiological and behavioral studies involving both animal and human populations
generally support this view (see Shelton & Tomarken, 2001), more research, particularly
clinical trials, is needed to replicate previous findings and to uncover the specifics of the
neurobiological mechanisms involved. The present study seeks (in part) to replicate the
initial findings of Knutson et al. (1998) and Boyer at al. (2000). Unlike those studies,
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however, the present study will (a) use the tripartite model as a theoretical basis and
conceptual guide for forming symptom clusters and (b) compare the effect of different
treatment modalities (PT, CBT and placebo) on these distinct symptom clusters.
Cognitive behavior therapy (CBT). Cognitive behavior therapy (CBT) for
depression and anxiety includes a variety of strategies such as modification of
maladaptive beliefs in order to improve affect, behavioral activation, exposure to
distressing situations and others (e.g., Beck, 1995; Beck, Emery & Greenberg, 1985;
Beck., Rush, Shaw & Emery, 1979). While CBT has consistently been found at least as
effective as other psycho- or pharmacotherapies in the acute treatment of mild to
moderate depression (Blackburn & Moore, 1997; Dobson, 1989; Gloaguen, Cottraux,
Cucherat & Blackburn, 1998; Hautzinger, de Jong-Meyer, Treiber & Rudolf, 1996;
Hollon, Shelton & Loosen, 1991; Robinson, Berman & Neimeyer, 1990), the efficacy of
CBT in the treatment of severe depression is less well established. The APA guidelines
recommend that CBT should not be used without PT for treating severe depression. Yet,
as noted by DeRubeis, Gelfand, Tang and Simons (1999) as well as Hollon, Haman and
Brown (2002), this recommendation is not entirely consistent with research findings
regarding the treatment of severe depression. In a mega-analysis (i.e. meta-analysis of
original data) conducted by DeRubeis and colleagues (1999) using data from four
randomized clinical trials (169 patients total), CBT performed as well as tricyclic
antidepressants in the treatment of severely depressed outpatients. More recent studies
have further supported findings that CBT is equally effective as PT in the acute treatment
of severely depressed outpatients (for review, see Hollon & Beck, 2002; for a discussion
of this research, see DeRubeis et al., 1999; Hollon & Shelton, 2001; Klein, 2000).
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Although CBT is an effective treatment for depression, and depression includes
symptoms of GD and ANH one cannot infer, however, that CBT works equally well for
both of these symptom clusters. Instead, it is entirely possible that CBT addresses one of
the symptom clusters more effectively (or faster) than another. Although CBT has been
found to be effective in treating both depression and anxiety disorders (e.g. Chambless &
Gillis, 1996), and many basic intervention strategies such as the cognitive restructuring
can be applied to both depression and anxiety, some strategies may target some symptom
dimensions more effectively than others. It could be speculated, for instance, that
behavioral activation targets symptoms such as inertia and lack of motivation consistent
with the cluster ANH. This would be consistent with the idea that behavioral activation
increases level of activity and positive engagement with the environment, and with the
fact that this strategy is used successfully in the treatment of depression (Jacobson,
Martell & Dimidjian, 2001; Martell, Addis & Jacobson, 2001), but not in the treatment of
anxiety.
In summary, depression is a multidimensional illness which can be characterized by
different symptom clusters. The tripartite model represents one way to conceptualize
symptom clusters, which may have important implications for the treatment of
depression. The investigation of differential treatment effects on symptom dimensions
consistent with the tripartite model may ultimately prove useful in the process of
assigning the best treatment strategies to each depressed individual.
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CHAPTER II
THE PRESENT STUDY
The primary aims of the present study were to use the tripartite model as a theoretical
framework in order to (1) investigate change in the constructs GD, ANH and SA in a
moderately to severely depressed sample over the course of treatment, (2) investigate
between-treatment (PT versus CBT) effects on the growth trajectories of GD, ANH, and
SA, and (3) investigate effects of pre-treatment comorbid anxiety diagnoses on intake
levels and change trajectories of GD, ANH, and SA. Rather than assessing each
construct by only one measure (i.e., manifest indicator), multiple indicators were used to
model GD, ANH, and SA as latent constructs. Manifest indicators were parcels of
selected items drawn from standard depression and anxiety symptom measures. Sub-
goals for this aim therefore included to (a) form item parcels consistent with the three
clusters of the tripartite model from the existing measures, and (b) test a three-factor
structure consistent with the tripartite model in the current data via confirmatory factor
analysis. The current study addressed the following hypotheses (H):
Three – factor structure. Based on previous empirical support for the tripartite
model, it was hypothesized that a three factor-structure consistent with the tripartite
model dimensions would provide at least adequate fit for data derived from a depressed
outpatient sample (H 1).
Treatment differences in change curves of ANH, GD, and SA. The main analyses
were aimed at modeling change in ANH, GD, and SA over the course of treatment and at
investigating treatment differences in growth trajectories. Both treatments, PT and CBT,
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were expected to lead to improvement in all three dimensions of the tripartite model
(H 2). Based on previous findings suggesting that serotonergic agents are particularly
effective in treating symptoms consistent with general distress and anxiety as compared
to symptoms consistent with anhedonia and low PA (Bodkin et al., 1997; Knutson et al.,
1998; Shelton and Tomarken, 2001), together with the absence of equivalent findings for
CBT, PT was expected to be superior to CBT in reducing symptoms consistent with GD
(H 3). With regard to ANH, there were two alternative lines of reasoning: The
comparatively lower benefit of serotonergic agents in the treatment of symptoms
consistent with ANH together with the speculation that behavioral activation, a technique
emphasized in the early stages of CBT in this study, specifically targets symptoms of
anhedonia by increasing pleasure and mastery experiences, it was hypothesized that ANH
would increase as (or more) rapidly in the CBT condition as in the PT condition (H 4a).
On the other hand, the constructs of state NA and PA have been found to be linked and at
least moderately correlated (e.g., Feldman Barrett & Russell, 1998; Tellegen, Watson &
Clark, 1999), which may lead to the hypothesis that GD and ANH would improve
simultaneously and thus ANH will show equivalent patterns of change to GD, i.e.
improve more rapidly with PT than with CBT (H 4b). SA was expected to be very
closely related to GD (Brown, Chorpita & Barlow, 1998) and improvement in SA was
therefore expected to closely follow the pattern of GD, i.e. show more rapid improvement
with PT than with CBT (H 5).
The effect of comorbid anxiety disorders at intake on the change curves of ANH,
GD, and SA over the course of treatment. Based on findings by Watson, Clark and
Carey (1988) and by Brown and colleagues (1998) that ANH is relatively specific to
depression (as compared to anxiety), pre-treatment ANH was not expected to differ
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between participants with pre-treatment comorbid anxiety disorder versus those without
(H 6). The above mentioned studies found GD to be shared by depression and anxiety.
Although these studies did not conclude that GD would be additive for comorbid
conditions both individually associated with GD, it was nevertheless hypothesized that
pre-treatment GD would be elevated in individuals with any pre-treatment comorbid
anxiety diagnoses (H 7). Based on evidence for a close relation between panic disorder
and SA (Brown et al., 1998), it was predicted that pre-treatment SA would be
significantly higher in participants with comorbid panic disorder, yet would not be
associated with any other comorbid anxiety disorder (H 8). Further, GD was
hypothesized to be present in other forms of psychopathology as well (Shelton &
Tomarken, 2001) and thus the presence of any pre-treatment comorbid Axis I condition
was expected to be associated with higher levels of pre-treatment GD, but not ANH or
SA (H 9). Finally, exploratory analyses were performed using comorbid anxiety
diagnoses at intake as predictors of change in ANH, GD, and SA over the course of
treatment.
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CHAPTER III
METHODS
This study is based on an existing data set from a two-site comparison of CBT versus
PT in the treatment of depression and the prevention of subsequent relapse (DeRubeis et
al., 2005; Hollon et al., 2005). Methodology and main findings of the CPT II project
have been presented elsewhere (DeRubeis et al., 2005; Hollon et al., 2005). The CPT II
project included three treatment conditions: PT, CBT, and pill placebo. Unlike the two
active treatment conditions, PT and CBT, each 16 weeks in duration, the placebo
condition was only eight weeks in duration and was therefore not included in the current
analyses. The following describes the methods of this project as they pertain to the
current study.
Sample
Participants for CPT II were recruited at the Adult Psychiatry Clinic at Vanderbilt
University Medical Center and at the Depression Research Unit at the University of
Pennsylvania. The current sample consisted of 181 depressed outpatients, 92 from
Vanderbilt and 89 from the University of Pennsylvania. Participants were primarily
Caucasian (82.9%) and had an average of 14.6 (SD = 2.4) years of education. The reader
is referred to DeRubeis et al. (2005) for between-site comparisons of patient
characteristics and treatment effects. There were 119 participants in the PT condition
(mean age = 39.81, SD = 11.65; 70 females) and 62 in the CBT condition (mean age =
40.18, SD = 11.36, 35 females). All participants met criteria for Major Depressive
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Disorder according to the DSM-IV and received a score of 20 points or higher on the 17-
item version of the HRSD for the two weeks preceding treatment (in two separate
evaluations). The average HRSD score for the 17-item version at intake was 23.62 (SD =
2.80) and did not differ significantly between groups.
Individuals were excluded if they met any of the following criteria: lifetime history of
psychotic disorders or bipolar disorder; history of substance dependence in the past year;
medical conditions which would interfere with study medications; other Axis I disorders
if they were more in need of treatment than depression (five patients diagnosed with
anxiety disorder were excluded for this reason); risk for suicide; current treatment with
certain psychoactive medications; or failure to respond to either paroxetine or CBT
within the preceding year (individuals who failed to respond to other kinds of treatments
were not excluded). Minimal exclusion criteria together with the requirement of high
levels of depression severity produced a sample of outpatients with relatively severe
depression and high rates of comorbid disorders.
Design and Procedure
Participants were recruited from the community and from clinical referrals.
Interested individuals participated in a pre-screening interview which included a brief
diagnostic assessment and the HRSD. After informed consent was obtained, an extensive
intake evaluation was performed. It included the Structured Clinical Interview for DSM-
IV Axis I Disorders-Patient Version (SCID-I/P; First, Spitzer, Gibbon & Williams, 1994)
as primary assessment tool for Axis I disorders. In context of the CPT II project,
interrater reliability for the assessment of criteria for a Major Depressive Episode
produced a kappa coefficient of .80 (n=12; cited in DeRubeis et al., 2005). In addition,
27
intake diagnoses were independently assessed by experienced psychiatrists. A physical
exam and a standard medical battery were used to rule out medical conditions which
could interfere with the study medication. One week after the original evaluation, a re-
screen assured continued endorsement of full criteria for major depressive disorder and a
score of 20 or higher on the HRSD. All patient assessment procedures were performed
by evaluators, who met weekly for training and supervision. Interrater agreement for the
17-item version of the HRSD was found to be exceptional with an Intraclass Correlation
Coefficient (ICC) of .96 (N=24; cited in DeRubeis et al., 2005).
Participants who met study criteria were randomized to the treatment conditions. The
following blocking variables were used (in order): sex, marital status, melancholic
subtype and number of prior episodes of depression. Within seven days of
randomization, participants started treatment. Although some measures were assessed
more frequently, all of the measured considered for the present study were administered
at the initial intake evaluation, at weeks 8 and 16. Treatment providers and evaluators
were blind to medication conditions.
Treatment Conditions
Cognitive Behavior Therapy (CBT). Sessions were performed according to the
treatment manuals by Beck and colleagues (e.g., Beck, 1995; Beck et al., 1979).
Generally, CBT aims at the identification and evaluation of maladaptive beliefs and
reasoning in order to derive at more adaptive and realistic thought processes (cognitive
restructuring). According to the theoretical background of this approach, the content of
thoughts and beliefs is linked to specific states of affect. Therapy is therefore based on
the assumption that changes in thinking can achieve changes in feeling. Sessions were
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highly structured, yet treatment placed emphasis on fostering growing independence in
participants. Further, therapy initially focused heavily on behavioral activation, and later
on practicing strategies to cope with distressing life events and other triggers of
depression in the future. Cognitive restructuring was emphasized throughout treatment.
However, therapists were free to apply certain other strategies such as exposure or
relaxation training when appropriate. Generally, 50-minute sessions were scheduled
twice per week for the first four weeks, once or twice per week for the next four weeks,
and weekly during the remaining eight weeks.
Pharmacotherapy (PT). The main study medication was paroxetine, which was
started at 10-20 mg daily and increased in 10-20 mg increments over subsequent weeks
up to a maximum of 50 mg daily by the end of week 6 (or until the patient remitted).
Generally, patients who did not meet criteria for partial remission by week 8 were
augmented with lithium or desipramine; however, on occasion other medications were
used in order to maximize clinical response to PT. As described in DeRubeis et al.
(2005), average doses of paroxetine were 14 ± 4.9 mg/day during the first week of
treatment, 31.6 ± 11.2 mg/day during the fourth week, 38.8 ± 11.0 by week 8, and 37.3 ±
12.4 mg/day during weeks 9 through 16. Clinical management sessions were held
weekly during the first four weeks of treatment and after that were held at least biweekly.
Clinical management sessions (lasting approximately 20 minutes) were conducted for
medication management, which allowed general supportive procedures. Experienced
pharmacotherapists supervised the implementation of PT.
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Measures
In order to assess the latent constructs ANH, GD, and SA, items were drawn from the
following measures:
The Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960). The HRSD is
a semi-structured interview, in which a trained evaluator assesses depression severity
during the previous week (see Appendix A). Trained evaluators rated 24 items on (3- and
5-point) Likert scales ranging from symptoms being absent to severe. In this study, the
HRSD was modified to include atypical symptoms (Thase, Frank, Mallinger, Hamer &
Kupfer, 1992) and administered according to the interview guide by Williams (1988).
All 24 items were considered for constructing item parcels. Interrater reliability has been
found to greatly improve with training of the interviewers (Clark & Watson, 1991). In
the original publication, Hamilton (1960) reported an interrater reliability of .90 for the
17-item version.
The Hamilton Rating Scale for Anxiety (HRSA; Hamilton, 1959). The HRSA is a
14-item semi-structured interview similar to the HRSD. The HRSA assesses the severity
of symptoms of anxiety during the past week (see Appendix B). Evaluators rate the
severity of anxiety symptoms on a 5-point scale ranging from none (0) to very severe (4).
Not much information is available on the psychometric properties of the HRSA.
Available sources have reported good interrater reliability for this measure (e.g., Gjerris
et al., 1983); the original article by Hamilton (1959) reported an interrater reliability of
.89.
The Beck Depression Inventory – II (BDI-II; Beck & Steer, 1987). The BDI-II is a
21-item questionnaire, in which participants rate the severity of their depression
symptoms averaged over the previous week (see Appendix C). Specifically, the
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participant chooses one of four phrases representing different levels of severity of a
particular symptom. Original psychometric tests of the BDI-II by Beck, Steer, and
Brown (1996) revealed excellent internal consistency in both outpatients (Cronbach
coefficient alpha = .92) and college students (coefficient alpha = .93). The original BDI,
which shares most items with the BDI-II has also been shown to have high internal
consistency with estimates ranging from .76 and .95 in clinical populations (Beck, Steer
& Garbin, 1988).
The Beck Anxiety Inventory (BAI; Beck & Steer, 1990). The BAI is a 21-item self-
report inventory, which assesses severity of anxiety symptoms during the previous week
(see Appendix D). Items are rated on a four-point scale ranging from "it did not bother
me at all" (0) to "I could barely stand it" (3). This measure was specifically designed to
reduce overlap with depressive symptoms. The BAI has been shown to possess excellent
internal consistency in outpatients with coefficient alpha ranging from .92 to .94 (Beck,
Epstein, Brown & Steer, 1988; Fydrich, Dowdall, & Chambless, 1990).
The Positive and Negative Affect Scale (PANAS; Watson, Clark & Tellegen, 1988).
The PANAS is a 20-item self-report scale designed to assess affect over the past week.
This measure is based directly on the two-factor affect model and contains two scales, PA
and NA. These scales assess high PA and high NA. Each scale consists of ten affect
adjectives (e.g., distressed, excited). Participants rate on a scale ranging from one (very
slightly or not at all) to five (extremely) the degree to which the items describe their
mood over the past week. The PANAS scales have been extensively investigated for
their psychometric properties (see Watson & Vaidya, 2003). They have been shown to
have very good internal consistency with coefficient alphas ranging from .83 - .90 for the
NA scale and from .84 - .91 for the PA scale (Watson & Clark, 1994 as referenced in
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Watson & Vaidya, 2003). In this study, the PANAS items were administered as part of a
49-item scale containing a wide range of affect adjectives (see Appendix E for a copy of
the 49-item measure; PANAS items are bold).
Item Selection and Formation of Item Parcels
In order to assess the latent constructs, GD, ANH and SA, items were selected from
the HRSD, HRSA, BDI, BAI, and PANAS. Later, item parcels were formed and served
as observed indicators. Item parcels were created based on similarity and source of the
items in order to reduce the number of indicator variables as well as increase reliability of
indicators and normality of their distributions (e.g., Bandalos & Finney, 2001; Little,
Cunningham, Shahar, & Widaman, 2002; Little, Lindenberger, & Nesselroade, 1999).
The selection of items and the formation of item parcels were guided by the theory of the
tripartite model (Clark & Watson, 1991) and the factor analytic work on the MASQ by
Watson and colleagues (Watson et al., 1995a,b). Five volunteers with background in
clinical psychology and extensive experience with all involved measures (the author,
another advanced clinical psychology PhD student, and three doctoral-level clinical
psychologists) were recruited for a formal task involving the assignment of items to
categories. The experts independently assigned all items from the HRSD, HRSA, BDI,
and BAI to one (or none) of the six categories reflecting the MASQ subscales – General
Distress (Mixed symptoms), General Distress (Anxious symptoms), General Distress
(Depressive symptoms), Somatic Anxiety, Loss of Interest, and High Positive Affect –
based on resemblance of the item to items in the MASQ scales (see Appendix F). After
the task was completed, the three GD categories were merged and the categories Loss of
Interest and High Positive Affect formed the category Anhedonia, leaving three
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categories: ANH, GD, and SA. Included in further analyses were items assigned to the
same category by the author and at least three of the four remaining participants. With
regard to GD, items were included if four of five participants assigned the item to any of
the GD categories. Of the 85 total items, 56 items (66%) were selected based on these
criteria. The main reasons for the exclusion of items were poor fit with all categories and
good fit with more than one category. Four additional items were included in the study
after group consensus was achieved.
The formed parcels were also compared to results of exploratory factor analyses on
week 16 data (week 16 was chosen because it offered maximal variability in the data as
compared to earlier time points). Principal Axis factor analysis followed by the oblique
promax rotation was performed on the items of each measure separately and factors with
eigenvalues greater or equal to 1.0 were extracted. Factor-analytic results were largely
consistent with the conceptual formation of parcels, i.e. items grouped into the same
parcels tended to load highest on the same factors. Items were excluded from analyses if
they (a) loaded highest on a different factor than the other items in that parcel or (b)
showed poor differentiation between factors. A total of six items was excluded for this
reason.
Of the 54 selected items, those derived from the same original measure and placed in
the same category were grouped together to form ten item parcels (see Table 1). One
parcel, which consisted of GD items from the HRSD, was divided into two parcels,
HRSD_GDD (containing more depression related GD items) and HRSD_GD (containing
more anxiety related and mixed GD items). Two additional parcels were created based
on the PA and NA subscales of the PANAS.
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Table 1
Item Assignment to Parcels
Parcel Items MASQ Category
Hamilton Rating Scale for Depression
HRSD_ANH 7. Work and activities, 8. Psychomotor retardation
13. Energy, 14. Libido
Anhedonia
HRSD_GDD 1. Depressed mood, 2. Guilt, 3. Suicide
23. Hopelessness, 24. Worthlessness
General Distress
HRSD_GD 9. Agitation, 10. Feeling anxious
15. Hypochondriasis, 22. Helplessness
General Distress
HRSD_SA 11. Somatic anxiety Somatic Anxiety
Beck Depression Inventory
BDI_ANH 4. Loss of pleasure, 12. Loss of interest
15. Loss of energy, 20. Tiredness/ fatigue
21. Loss of interest in sex
Anhedonia
BDI_GD 1. Sadness, 2. Pessimism, 3. Past failure
5. Guilty feelings, 6. Punishment feelings
7. Self dislike, 8. Self criticalness
10. Crying, 14. Worthlessness
General Distress
Hamilton Rating Scale for Anxiety
HRSA_GD 1. Anxious mood, 2. Tension, 3. Fears General Distress
HRSA_SA 7. Muscular, 8. Sensory, 9. Cardiovascular
10. Respiratory, 13. Autonomic
Somatic Anxiety
Beck Anxiety Inventory
BAI_GD 4. Unable to relax, 5. Fear of the worst happening
9. Terrified, 10. Nervous, 17. Scared
General Distress
BAI_SA 1. Numbness or tingling, 2. Feeling hot
3. Wobbliness in legs, 6. Dizzy or lightheaded
7. Heart pounding or racing, 8. Unsteady
11. Feelings of choking, 12. Hands trembling
13. Shaky, 15. Difficulty breathing, 19. Faint
20. Face flushed, 21. Sweating
Somatic Anxiety
Positive and Negative Affect Scale
PA 1. proud, 2. interested, 3. excited, 4. strong
5. active, 6. attentive, 7. enthusiastic
8. determined, 9. inspired, 10. alert
Anhedonia
NA 1. hostile, 2. distressed, 3. irritable, 4. ashamed
5. upset, 6. scared, 7. afraid, 8. jittery
9. nervous, 10. guilty
General Distress
34
CHAPTER IV
RESULTS
Table 2 shows the descriptive statistics for the raw data of all twelve parcels
separately for both treatment groups and for three time points (intake, week 8, and
week 16). Individual items missing from a parcel were substituted with the mean. The
number of missing observations (i.e. whole parcels), can be inferred from the column N
in Table 2, which indicates the number of observations by parcel, time point, and
treatment condition. As each participant should have contributed one observation to each
cell, the number of missing observations equals the number of observations for a given
parcel at a given time point (N) subtracted from the total number of participants in each
treatment condition (N = 119 for PT and N = 62 for CBT). Missing observations varied
between parcels because in the CPT II project priority was given to collect data on HRSD
and BDI. Missing data ranged from 0 to10 % at intake, from 9 to 18 % at week 8, and
from 12 to18 % at week 16. In a longitudinal study such as the present one, this amount
of data is expected to be missing for a variety of random (e.g., schedule conflict, move,
etc.) and more systematic reasons (e.g., sickness, attrition, etc.).
Natural logarithmic transformation (y = ln (x + 5)) was performed on all parcels in
order to normalize the distributions. This transformation reduced skewness (an indicator
of the asymmetry of the distribution) and kurtosis (an indicator of the clustering of
observations) values. After the transformation, skewness ranged from -0.74 to 1.49 in the
CBT group and from -1.07 to 1.94 in the PT group, kurtosis ranged from -1.03 to 3.78 in
CBT and from -0.91 to 3.54 in PT.
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Table 2
Descriptive Statistics for the Item Parcels (Prior to Log-Transformation):
Pharmacotherapy Condition (N=119)
Parcel N M SD Possible
range
Min Max Skewness Kurtosis
Intake
PA 116 1.56 0.51 1-5 1.00 3.30 1.32 1.65
NA 116 2.77 0.81 1-5 1.00 4.80 0.21 -0.54
HRSD_ANH 119 2.31 0.56 0-4 0.63 3.25 -0.48 -0.25
HRSD_GDD 119 1.85 0.51 0-4 0.50 3.10 -0.16 -0.14
HRSD_GD 119 1.05 0.35 0-4 0.25 2.13 0.44 0.23
HRSD_SA 119 1.84 0.65 0-4 0.00 3.00 -0.78 0.55
BDI_ANH 107 1.81 0.56 0-3 0.70 3.00 0.21 -0.61
BDI_GD 107 1.53 0.52 0-3 0.22 2.89 0.30 0.29
HRSA_GD 111 1.35 0.54 0-4 0.17 2.67 -0.13 -0.31
HRSA_SA 111 0.68 0.45 0-4 0.00 2.40 0.68 0.79
BAI_GD 114 1.24 0.68 0-3 0.00 3.00 0.21 -0.52
BAI_SA 114 0.48 0.45 0-3 0.00 1.77 1.20 0.79
Week 8
PA 97 2.43 0.88 1-5 1.00 4.40 0.36 -0.49
NA 97 1.87 0.70 1-5 1.00 4.10 0.92 0.49
HRSD_ANH 108 1.36 0.89 0-4 0.00 3.25 0.29 -0.74
HRSD_GDD 108 0.79 0.70 0-4 0.00 3.00 1.14 0.84
HRSD_GD 108 0.52 0.41 0-4 0.00 1.75 0.59 -0.07
HRSD_SA 108 1.31 0.93 0-4 0.00 3.00 0.20 -0.81
BDI_ANH 102 0.88 0.70 0-3 0.00 3.00 1.21 1.56
BDI_GD 102 0.58 0.58 0-3 0.00 2.44 1.19 1.03
HRSA_GD 106 0.67 0.51 0-4 0.00 2.00 0.48 -0.40
HRSA_SA 106 0.41 0.38 0-4 0.00 1.80 1.42 2.07
BAI_GD 100 0.45 0.53 0-3 0.00 2.80 1.76 3.93
BAI_SA 101 0.25 0.29 0-3 0.00 1.46 1.50 3.02
Week 16
PA 101 2.53 0.94 1-5 1.00 5.00 0.21 -0.74
NA 101 1.69 0.73 1-5 1.00 4.10 1.58 2.18
HRSD_ANH 105 0.95 0.86 0-4 0.00 3.50 0.74 -0.11
HRSD_GDD 105 0.60 0.66 0-4 0.00 2.60 1.38 1.10
HRSD_GD 105 0.41 0.39 0-4 0.00 1.75 1.15 1.20
HRSD_SA 105 1.17 0.87 0-4 0.00 3.00 0.28 -0.63
BDI_ANH 100 0.66 0.70 0-3 0.00 3.00 1.45 2.13
BDI_GD 100 0.37 0.47 0-3 0.00 2.22 1.73 3.04
HRSA_GD 101 0.56 0.58 0-4 0.00 3.00 1.43 2.67
HRSA_SA 101 0.40 0.39 0-4 0.00 1.40 0.96 0.18
BAI_GD 98 0.34 0.54 0-3 0.00 2.80 2.19 5.09
BAI_SA 98 0.25 0.26 0-3 0.00 1.08 1.27 1.23
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Table 2, continued
Descriptive Statistics for the Item Parcels (Prior to Log-Transformation): Cognitive
Behavior Therapy Condition (N = 62)
Parcel N M SD Possible
range
Min Max Skewness Kurtosis
Intake
PA 61 1.73 0.61 1-5 1.00 3.40 1.14 0.74
NA 61 2.76 0.74 1-5 1.30 4.60 0.23 -0.28
HRSD_ANH 62 2.31 0.46 0-4 1.13 3.25 -0.17 -0.14
HRSD_GDD 62 1.81 0.49 0-4 0.90 2.90 0.00 -0.80
HRSD_GD 62 1.08 0.35 0-4 0.50 2.00 0.83 0.45
HRSD_SA 62 2.06 0.68 0-4 0.50 4.00 0.16 0.36
BDI_ANH 58 1.73 0.52 0-3 0.40 2.80 -0.09 -0.20
BDI_GD 58 1.43 0.44 0-3 0.50 2.56 0.23 -0.16
HRSA_GD 56 1.43 0.68 0-4 0.00 4.00 1.63 6.03
HRSA_SA 56 0.82 0.57 0-4 0.00 3.00 1.23 2.79
BAI_GD 60 1.27 0.70 0-3 0.00 3.00 0.41 0.14
BAI_SA 60 0.56 0.52 0-3 0.00 2.31 1.39 1.68
Week 8
PA 53 2.32 0.78 1-5 1.00 3.90 0.26 -0.87
NA 53 2.31 0.84 1-5 1.00 4.40 0.57 -0.54
HRSD_ANH 53 1.48 0.69 0-4 0.00 2.75 -0.09 -0.55
HRSD_GDD 53 0.98 0.66 0-4 0.00 2.60 0.67 -0.34
HRSD_GD 53 0.64 0.38 0-4 0.00 1.75 0.40 0.23
HRSD_SA 53 1.57 0.80 0-4 0.00 3.00 -0.46 -0.21
BDI_ANH 54 1.01 0.64 0-3 0.00 2.80 0.68 0.58
BDI_GD 54 0.76 0.57 0-3 0.00 2.67 0.80 0.90
HRSA_GD 52 1.08 0.64 0-4 0.00 3.33 0.87 1.72
HRSA_SA 52 0.58 0.44 0-4 0.00 1.60 0.59 -0.50
BAI_GD 51 0.68 0.50 0-3 0.00 2.20 0.51 0.10
BAI_SA 52 0.27 0.36 0-3 0.00 1.46 1.68 2.38
Week 16
PA 53 2.48 0.80 1-5 1.00 4.30 0.17 -0.46
NA 53 1.88 0.67 1-5 1.00 3.50 0.67 -0.19
HRSD_ANH 54 1.13 0.86 0-4 0.00 3.00 0.37 -0.83
HRSD_GDD 54 0.71 0.71 0-4 0.00 2.80 0.96 0.19
HRSD_GD 54 0.51 0.48 0-4 0.00 2.25 1.47 2.78
HRSD_SA 54 1.09 1.00 0-4 0.00 4.00 0.52 -0.24
BDI_ANH 51 0.75 0.72 0-3 0.00 3.00 1.00 0.68
BDI_GD 51 0.48 0.54 0-3 0.00 2.67 1.81 4.22
HRSA_GD 54 0.80 0.78 0-4 0.00 4.00 1.87 4.72
HRSA_SA 54 0.46 0.47 0-4 0.00 1.80 1.07 0.46
BAI_GD 51 0.47 0.49 0-3 0.00 1.80 1.19 1.11
BAI_SA 51 0.22 0.28 0-3 0.00 0.92 1.19 0.12
Note. PA = Positive Affect (NA = Negative Affect) items of the Positive and Negative Affect Scale;
HRSD = Hamilton Rating Scale for Depression, HRSA = Hamilton Rating Scale for Anxiety, BDI = Beck
Depression Inventory, BAI = Beck Anxiety Inventory, ANH = Anhedonia, GD = General Distress, SA =
Somatic Anxiety; HRSD_ANH refers to items from the HRSD consistent with ANH, etc.
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Confirmatory Factor Analyses with Factor ANH, GD, and SA
Confirmatory factor analysis (CFA) was performed with all twelve parcels serving as
indicator variables and three structural correlated factors representing ANH, GD, and SA.
The intention of the CFA was to test whether symptom clusters representative of the
tripartite model components can be distinguished in the current data. For the purpose of
testing a specific, theoretically derived factor structure, CFA is considered more
appropriate than exploratory factor analytic techniques. It provides a more stringent test
of an a priori hypothesized factor structure and allows for a direct comparison of the
hypothesized model to alternative models.
The program AMOS 4.0 (Arbuckle, 1999) was used to perform all structural equation
modeling (SEM) including these CFAs and all latent growth analyses below. Casewise
maximum likelihood (ML) estimation was used to address the presence of missing data.
Compared to other methods such as listwise deletion or imputation methods, ML
estimation has been found to provide more efficient estimates when data are missing
completely at random or at random and reduce bias caused by data missing for other
reasons (e.g., Arbuckle, 1996).
The following indices were chosen to evaluate model fit: the chi-square goodness-of-
fit statistic (2; described, for example, in Hu & Bentler, 1998), the comparative fit index
(CFI; Bentler, 1990), the Tucker-Lewis Index (TLI; Tucker & Lewis, 1973), and the root
mean squared error of approximation (RMSEA; Steiger & Lind, 1980). At a general
level, these indices all estimate discrepancies between the relations among the measured
variables (i.e., the observed covariance matrix) to the relations among the variables
implied by the model (i.e., the hypothesized covariance matrix).
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The chi-square test is one of the most widely used fit indices in SEM research, which
tests the null hypothesis that the model provides a perfect fit. Thus, a significant chi-
square test typically suggests lack of model fit, i.e. “a significant amount of actual
covariance between measures remains unexplained by the model” (Cole, 1987, p. 585).
One of the advantages of the chi-square test is its sensitivity to model misspecification;
disadvantages include high sensitivity to violations of multivariate normality and to
sample size. For larger sample sizes and non-normal data, it reaches significance with
rather small discrepancies between the covariance matrix predicted by the model and the
actual one derived from the data. A significance level of p = 0.05 is frequently
considered too stringent and other conventions for adequate model fit include a ratio of
the chi-square statistic to the degrees of freedom of less than 3 (Carmines & McIver,
1981) or 5 (Wheaton, Muthén, Alwin, & Summers, 1977).
The chi-square test is also used as a tool for comparing hierarchically nested models
in the present study. Models are hierarchically nested when one model can be derived
from the other by fixing one or more variables (Loehlin, 2004, p. 62). The difference ()
between the chi-square statistics from two nested models is also distributed as chi-square.
The degrees of freedom (df) for this chi-square difference test equals the difference
between the df’s of the separate chi-square tests. A significant chi-square difference test
indicates that one model provides significantly better fit for the data than the other.
It is recommended to use a variety of different fit indices which vary in strengths and
weaknesses (Hu & Bentler, 1998). Thus, in addition to the chi-square test, CFI and TLI
were chosen because they are less sensitive to fluctuations in distributions and sample
size (Hu & Bentler, 1998). Unlike the CFI, the TLI rewards for parsimony of the model.
According to Hu and Bentler (1998), for both CFI and TLI, values of .095 or greater
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indicate good fit in structural equation models. Finally, the RMSEA, like the chi-square
test, has a known distribution which allows for the calculation of a confidence interval
and a significance level for the estimated fit. In general, a RMSEA 0.06 or less indicates
good fit (Hu & Benter, 1998). CFI, TLI, and RMSEA have all been shown to have high
sensitivity to a variety of model misspecifications (for reviews of these and other fit
indices, see Bentler & Bonett, 1980 and Hu & Bentler, 1998).
In order to assure independent observations, only one set of observations (i.e., one
time point) was included in the analyses. Although post-treatment data do not include all
participants (due to attrition), which may present a possible bias for the model estimates,
week 16 data were chosen in order to assure maximal range of scores. Intake data were
expected to have highly restricted variance in ANH and GD due to the severe levels of
depression. Restricted variance artificially boosts correlations among observed variables
and poses problems for the identification of separate factors.
Given that parcels were derived from different measures, variability between parcels
was expected to be in part due to method variance. Assessment methods in this study
were grouped into self-report versus interview-based assessment. Therefore, two
(correlated) method factors, Self (indicating self-reported data) and Interview (indicating
data collected via clinical interview) were included in the model. All factor variances
were fixed at one. Error term variances were estimated for the observed variables.
Loadings for error terms were fixed at one. In addition, intercept terms were estimated
for observed variables as part of the ML estimation for missing data.
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Figure 2. Three-Factor Model (Standardized Solution). N = 159 (data collected at week 16).
ANH = Anhedonia factor; GD = General Distress factor; SA = Somatic Anxiety factor; Self =
Self-Report method factor; Interview = Interview-based method factor. For description of
parcels, see Table 2. Factor variances were fixed at one in order to avoid under-identification of
the model. Parameter estimates associated with the curved arrows indicate correlations between
factors. Straight arrows indicate one-directional influences. Error terms are omitted from the
figure for clarity.
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A drawing of the tested CFA model with standardized parameter estimates is depicted
in Figure 2. Fit indices for this three factor model (N=159) indicated excellent global fit:

2 (df = 38, N= 159) = 40.20, p = 0.373, comparative fit index (CFI) = 1.000, Tucker-
Lewis Index (TLI) = 1.000, root mean squared error of approximation (RMSEA) = 0.019,
90% CI = [0.000, 0.060]. The necessity of the method factors was tested by direct
comparison of the original three-factor model with a nested model without the method
factors (i.e., with loadings and covariance of the method factors constraint to zero). The
chi-square difference test indicated significant deterioration of model fit (2 (13) =
110.68, p = 0.000) strongly arguing for the requirement of method factors or alternative
ways of modeling method variance such as allowing error terms to correlate.
The three-factor model and the standardized parameter estimates are depicted in
Figure 2. All factor loadings for the structural factors were highly significant (all p <
.001) and consistent with the tripartite model. As can be seen in Figure 2, correlations
among the latent constructs ANH, GD, and SA were fairly high (ranging from .61 to .78)
and highly significant (for all, p < .001). These high correlations indicate that the
constructs share a significant amount of variance. Correlation between the two method
factors was also highly significant (p < .001).
The three-factor model was further compared to a four-factor and a two-factor model.
The proposed four-factor structure was informed by empirical work by Watson et al.
(1995a, b) and by Burns and Eidelson (1998) and divides the GD factor into GDD and
GDA (see Figure 3).
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Figure 3. Four-Factor Model (Standardized Solution). N = 159 (data collected at week 16).
GDD = General Distress Depression factor; GDA = General Distress Anxiety factor; see Figure 2
for a description of the remaining factors, and model features.
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Fit indices indicated very good fit for the four-factor model as well (2 (df = 35, N =
159) = 46.58, p = 0.091, CFI = 0.999, TLI = 0.998, RMSEA = 0.046, 90% CI = [0.000,
0.078]). Direct comparison indicated a non-significant trend for the three-factor model to
be superior to the four-factor model (2 (3) = 6.38, p = 0.096). There were several
aspects of four-factor model, which made it difficult to interpret. Problems included the
fact that factor loadings were less consistent with the tripartite model and in fact,
appeared less interpretable in general. Method factors were highly correlated (.95)
making them nearly indistinguishable. Parcels loaded consistently more highly on the
method factors than on the four structural factors meaning that the “method factors”
accounted for more of the variance in the parcels than the other factors and suggesting
that in fact they accounted for variance other than that due to shared methods. In sum, in
the presented form, the four-factor model, though statistically providing good fit for the
data, is difficult to interpret theoretically and therefore a poor model.
In addition, a two-factor model was tested for which the factors ANH and GDD were
merged to a factor for Depression, and GDA and SA were merged to form a factor for
Anxiety. Fit indices suggest a poor fit of the two-factor structure (2 (df = 41, N = 159) =
107.44, p = 0.000, CFI = 0.994, TLI = 0.989, RMSEA = 0.101, 90% CI = [0.078, 0.125]).
Although the two-factor model could not be directly compared to the three-factor model
(as they were not nested), direct comparison to the four-factor model indicated a
significantly inferior fit for the former (2 (6) = 60.86, p < 0.001). Given that the four-
factor model was itself inferior to the three-factor model (at the level of a non-significant
trend), this suggests that the two-factor structure was also inferior to the three-factor
structure.
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As tests of invariance of the individual constructs (described below) revealed
instability of GD across time, three of the six parcels loading on GD were removed from
the model (HRSD_GDD, BDI_GD, and BAI_GD). The resulting narrower construct of
GD was based on the parcels HRSD_GD, HRSA_GD and NA and was more stable
across time. This “reduced three-factor model” (depicted in Figure 4) also fit the data
very well (2 (df = 14, N = 159) = 11.20, p = 0.671, CFI = 1.000, TLI = 1.001, RMSEA =
0.000, 90% CI = [0.000, 0.062]). Figure 4 shows that factor loadings for the factors
ANH, GD, and SA were high (and significant with p < .001 in all cases) indicating
further consistence with the hypothesized three-factor structure. Correlations among the
Figure 4. Reduced Three-Factor Model (Standardized Solution). N = 159. Factors and other
features of the model are equivalent to the original three-factor model in Figure 2.
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latent constructs ANH, GD, and SA were slightly smaller than in the original three-factor
model (Figure 2) and were also significant (for all, p < .001). Correlation between the
method factors was not significant at the .05 level.
In sum, for purposes of the present study, the three-factor model found good support
in the present data. Yet, it should be emphasized that the present study does not claim to
directly evaluate the construct validity of the tripartite model structure. Many other,
statistically equivalent and non-equivalent models may fit the data equally well or even
better (e.g., MacCallum, Wegener, Uchino, & Fabrigar, 1993; for a discussion see
Tomarken & Waller, 2003).
Testing for Measurement Invariance Across Time and Groups
Before growth and treatment effects in the latent constructs ANH, GD, and SA, were
modeled, measurement invariance of these constructs across time and groups was
assessed. Meaningful interpretation of change in latent constructs across time as well as
between-group differences relies on the assumption that the same construct is assessed
across time and across groups. Yet, even the use of equivalent measures across time and
groups alone does not assure measurement invariance (particularly with relatively small
sample sizes like the ones in the present study). Various different components of a model
could be (individually or simultaneously) tested for invariance (e.g., residual factor
variances, error term variances and covariances, etc.), yet methodology experts seem to
agree that the invariance of factor loadings, i.e. the mapping of observed variables onto
latent variables, is the key issue of interest in this context (e.g., Alwin & Jackson, 1981;
T. E. Duncan, S. C. Duncan, Strycker, Li & Alpert, 1999).
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Invariance of factor loadings (hereafter also referred to as ‘construct invariance’ or
‘construct stability’) was tested across three time points (intake, week 8, and week 16)
and across groups (PT and CBT) using nested models. Baseline models with freely
estimated factor loadings (depicted in Figure 5) were compared to restricted (yet
otherwise identical) models with factor loadings constrained to be equal across time
and/or across groups. The chi-square difference test was used in order to assess whether
equality constraints led to significant deterioration in model fit, which in this case would
indicate a lack of invariance.
For both baseline and restricted models, variances and covariances of latent
constructs were freely estimated and not constrained to be equal. Error term variances
were freely estimated and allowed to covary for equivalent parcels across time. The
rational for the allowance of correlated error variances were the shared assessment
methods1. First, invariance across time (i.e., factor loadings constraint to be equal across
time) was tested for each group separately, and then invariance across time and across
groups was tested in analyses combining both groups.
As can be seen in Table 3, these constraints did not lead to significant deterioration in
model fit in any of the constructs when tested separately for CBT and PT (p  0.074 for
all chi-square difference tests). After establishing sufficient stability of each construct
across time separately for each group, invariance was tested jointly for both groups in
two-group latent variable models.
1 Intercepts of latent constructs were fixed at zero. Intercepts for observed variables were freely estimated.
Error intercepts were fixed at zero. For GD, one error variance and some of the error covariances were set
to zero as noted in Table 3.
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PT group (N = 119)
CBT group (N = 62)
Figure 5. Hypothesized Model Involving Two Groups (PT and CBT) Testing Measurement
Invariance across Time and Groups. ANH t1-3 = Anhedonia Factor at time of intake, week 8, and
week 16, respectively. HRSD_ANH t1 = parcel HRSD_ANH assessed at intake, HRSD_ANH t2
= parcel HRSD_ANH assessed at week 8, etc. Equal labels of factor loadings indicate factor
loadings constrained to be equal; e1 – e9 = error terms. For description of parcels, see Table 1.
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Table 3
Fit Statistics for Models testing Measurement Invariance across Three Time Points
(intake, week 8, and week 16), for both Groups Individually and Combined
Model 2 df 2 /
df
TLI RMSEA Compare
to

2

df

2 /
df
p
Anhedonia: Medication group (N = 119)
I. Baseline 22.55 15 1.50 0.996 0.065
Invariance across time 23.65 19 1.25 0.998 0.046 I 1.11 4 2.78 0.893
Anhedonia: Cognitive therapy group (N = 62)
II. Baseline 9.58 15 0.64 1.005 0.000
Invariance across time 18.10 19 0.95 1.001 0.000 II 8.52 4 2.13 0.074
Anhedonia: Both groups (N =181)
III. Baseline: no constraints 32.11 30 1.07 0.999 0.020
Invariance across time 41.78 38 1.10 0.999 0.024 III 9.67 8 1.21 0.289
Invariance across groups 38.91 36 1.08 0.999 0.021 III 6.80 6 1.13 0.340
Invariance across time &
groups
41.89 40 1.05 1.000 0.016 III 9.77 10 0.98 0.461
General Distress: Medication group (N = 119)
I. Baseline 19.45 15 1.30 0.998 0.050
Invariance across time 20.88 19 1.10 0.999 0.029 I 1.43 4 0.36 0.839
General Distress: Cognitive therapy group (N = 62)
II. Baseline 23.68 18 1.32 0.996 0.072
Invariance across time 30.92 22 1.41 0.994 0.082 II 7.24 4 1.81 0.124
General Distress: Both groups (N =181)
III. Baseline: no constraints 44.74 36 1.24 0.998 0.037
Invariance across time 53.97 44 1.24 0.998 0.036 III 9.24 8 1.16 0.323
Invariance across groups 63.57 42 1.51 0.995 0.054 III 18.84 6 3.14 0.004
Invariance across time and
groups
68.68 46 1.49 0.995 0.052 III 23.95 10 2.40 0.008
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Table 3, continued
Fit Statistics for Models testing Measurement Invariance Across Three Time Points
(intake, week 8, and week 16), for Both Groups Individually and Combined
Model 2 df 2 /
df
TLI RMSEA Compare
to

2

df

2 /
df
p
Somatic Anxiety: Medication group (N = 119)
I. Baseline 15.34 15 1.02 1.000 0.014
Invariance across time 17.88 19 0.94 1.000 0.000 I 2.54 4 0.64 0.637
Somatic Anxiety: Cognitive therapy group (N = 62)
II. Baseline 19.29 15 1.29 0.996 0.068
Invariance across time 27.06 19 1.42 0.994 0.083 II 7.77 4 1.94 0.100
Somatic Anxiety: Both groups (N =181)
III. Baseline: no constraints 34.69 30 1.16 0.998 0.030
Invariance across time 45.03 38 1.19 0.998 0.032 III 10.35 8 1.29 0.242
Invariance across groups 45.20 36 1.26 0.998 0.038 III 10.51 6 1.75 0.105
Invariance across time and
groups
56.01 40 1.40 0.996 0.047 III 21.32 10 2.13 0.019
Note. 2 = chi-square test for model fit, df = degrees of freedom, TLI = Tucker-Lewis Index,
RMSEA = root mean squared error of approximation, 2 = chi-square test for difference in
model fit, df = degrees of freedom for the chi-square test for difference in model fit. Baseline
Model refers to all factor loadings being freely estimated, invariance across time refers to
a1=a2=a3, c1=c2=c3, aa1=aa2=aa3, and cc1=cc2=cc3, invariance across groups refers a1=aa1,
c1=cc1, a2=aa2, etc., invariance across time and groups refers to the combination of constraints
across time and groups. In order to fit the model of construct GD for group CT, the error term for
parcel HRSA_GD at t2 as removed. In the simultaneous test for invariance in both groups, error
covariance was set to zero in the PT group for the parcels HRSA_GD between t1 and t3 and
HRSA_GD between t2 and t3; for CT, error variance for HRSA_GD at t2 and error covariance
for this parcel across different time points was constrained to zero.
As displayed in Table 3, tests again indicated sufficient invariance of all constructs
across time (p  0.242 for all chi-square difference tests). In addition, ANH was found to
be invariant across treatment groups (p = 0.340) and jointly across time and groups
(p = 0.461). For GD, invariance across time could be established (p = 0.323), but
significant deterioration in fit of the model was detected when factor loadings were
50
constrained to be invariant across groups (p = 0.004) and jointly across groups and time
(p = 0.008). A number of interrelated factors may have contributed to these results
including (a) uneven sample size in the two treatment conditions (N = 119 in PT and N =
62 in CBT), (b) relatively small sample size in the CT group (not counting missing data,
the actually available N varied by parcel from 56 to 62 at intake, from 52 to 53 at week 8,
and from 53 to 54 at week 16), (c) a between-group difference in the factor structure of
GD before treatment, and (d) a change of the factor structure with treatment at least in
one of the groups. As the cause(s) of these findings cannot be disentangled at this time,
caution is warranted with regard to the interpretation of between-group (PT versus CBT)
differences in change of GD over time. Variability in the measurement of GD across
groups and across time may have raised the likelihood of obtaining significant effects for
treatment or other predictors.
For SA, measurement invariance could be established separately across groups
(p = 0.11) and across time (p = 0.24). Joint invariance across time and groups was less
clear. The Chi-square difference test indicated a significant difference between the fully
constrained and the fully unconstrained model indicating lack of invariance (p = 0.019).
However, change in other fit indices was fairly small (change in TLI = 0.002, change in
RMSEA = 0.017) and thus findings with regard to growth models and predictors of
growth in SA are considered sufficiently valid.
Modeling Growth
Latent growth modeling (LGM) was used to investigate change and predictors of
change in the constructs ANH, GD, and SA. LGM was chosen as data analytic technique
for its advantages over more traditional methods. LGM uses SEM methodology to
51
estimate individual growth trajectories as well as interindividual differences between
these trajectories. Compared to classic repeated measures analysis of variance
(ANOVA), which treats within-group variability as error, LGM is therefore better able to
address method variance and random changes in measurement error across time. In
addition, it can more flexibly address heterogeneity in error covariance, and missing data
(e.g., Duncan et al., 1999; Tomarken & Waller, 2005; Willet & Sayer, 1994). These
advantages are expected to translate into increased power and a more accurate reflection
of the sample characteristics. In addition, the SEM methodology (as described above for
CFA) offers the unique opportunity to evaluate actual fit of the hypothesized model used
to generate parameter estimates.
A standard first-order LGM, illustrated in Figure 6, describes individual growth
curves for variable (V) over time. V1 through V3 represent scores for a given individual
for the same observed variable across three equally spaced time points. The first factor
“Intercept” represents the initial (or average) score of V for a given individual. The
second factor “Slope” indicates the rate of change in this variable for this individual, and
the third factor “Quad” indicates the quadratic component or curvature of the change
trajectory of this variable for this individual. All three factors have means and variances
which respectively reflect the average tendency and variability of trajectories across
individuals in the sample. Parameterization for the hypothesized model was informed by
Duncan et al. (1999) and Hancock, Kuo, and Lawrence (2001). In Figure 6, the growth
factors are allowed to covary. For reasons described above, residual error terms of
equivalent variables (in this case the one observed variable) are also typically allowed to
covary across time.
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Figure 6. Representation of a Polynomial Latent Growth Model. V1 –V3 = variable across three
equally spaced time points, Intercept = factor representing the intercept of the growth trajectory,
Slope = factor representing rate of change in the variable, Quad = factor representing curvature of
change, e1-e3 = error terms. Means and variances are omitted from this representation for clarity.
For the following analyses, second-order latent growth models with multiple
indicators were used to investigate patterns of change for each of the three latent
constructs over the course of treatment. Specifically, the type of growth modeling used
here has been referred to as “curve-of-factor model” (McArdle, 1988), “latent variable
longitudinal curve model” (Tisak & Meredith (1990), and “second-order latent growth
model” (Hancock, Kuo, & Lawrence, 2001). Unlike first-order growth modeling of one
observed variables (described above), second-order LGM represents growth in latent
constructs assessed via multiple indicators. Given the fallibility of any individual
indicator in the assessment of a given construct, the use of multiple indicators is typically
V1 V2 V3
e1 e2 e3
Intercept Slope Quad
1 1 12
0
1 01
4
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preferable. This is particularly true in the present situation as no direct and validated
measure of the constructs ANH, GD, and SA was available. Figure 7 displays the model
for the latent construct ANH; models for the constructs GD and SA were equivalent (the
variable Treat will be explained further below).
Figure 7. Hypothesized Second-Order Latent Growth Model with Treatment as Predictor
(Dummy) Variable. d1-d6 = residual variance terms for the factors; e1-e9 = residual error terms
for the observed variables; for description of observed variables and factors, see Figures 2 and 5;
factor loadings for first-order factors were constrained to be equal across time with parcel
BDI_ANH was used as metric for the first-order factors; parameterization for second-order
growth factors followed Duncan et al. (1999) and reflects an interval of ten weeks between t1 and
t2 and 8 weeks between t2 and t3.
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Generally, in order to provide a scale for the first-order factors, either their variances
have to be fixed or one of the observed indicators is chosen to determine a metric for it.
The latter is performed by fixing the factor loading for this indicator at one for all time
points. In the present study, variances for first-order constructs were freely estimated and
one of the indicators served as metric. As can be seen in Figure 7, indicator BDI_ANH
served as metric for ANH (HRSA_GD served as metric for GD and HRSA_SA served as
metric for SA); factor loadings for the remaining indicator variables were estimated, but
constrained to be equal across time. Intercepts for equivalent observed variables were
constrained to be equal across time reflecting the assumption that equivalent indicator
variables share the same intercept across time, and differ only as a function of growth
(and error variance). Error variance and covariance were freely estimated with the
exception noted in Table 3. Disturbances for first-order factors were constrained to be
equal across time in order to prevent under-identification of the model; intercepts for
these factors were fixed at zero.
Second-order factors reflect the growth factors discussed above with Intercept
representing pre-treatment status in the latent construct, whereas Slope and Quad together
represent the pattern of growth in the construct across time. The quadratic factor was
included in order to test hypotheses regarding treatment effects on curvature of the
trajectories. The slope and the quadratic growth factors were expected to be correlated
and were thus allowed to covary. Factor loadings for the growth factors follow standard
procedures for growth modeling (e.g., Duncan et al., 1999) and took into account non-
equal spacing of time points. Intake assessment took place approximately two weeks
before the start of active treatment creating an average time interval of ten weeks between
time 1 (intake) and time 2 (week 8). This time interval was defined as one unit. The time
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interval between time 1 and time 3 (week 16) therefore equaled 1.8 time units (i.e., 18
weeks). Consequently, factor loadings were 0, 1, and 1.8 for the slope factor and 02, 12,
and 1.82 for the quadratic factor. To illustrate, growth in the latent construct ANH can
also be expressed in the following equations:
ANH t1 = 1 (Intercept) + 0 (Slope) + 02 (Quadratic) + d1 (1)
ANH t2 = 1 (Intercept) + 1 (Slope) + 12 (Quadratic) + d2 (2)
ANH t3 = 1 (Intercept) + 1.8 (Slope) + 1.82 (Quadratic) + d3 (3)
Ignoring interindividual differences, the average growth trajectory for ANH is
defined by time points 1, 2 and 3. As can be seen in equation (1), ANH at time 1 equals
the estimated mean of the intercept factor plus unexplained residual variance of ANH at
intake (no growth is added). The level ANH at time 2 is calculated by taking the
estimated mean of the intercept factor and adding (one unit of) the estimated mean of the
slope factor, (one unit of) the estimated mean of the quadratic factor, and a term
representing unexplained variance of ANH at time 2 (equation 2). Finally, the level of
construct ANH at time 3 is calculated equivalently to that at time 2 except that 1.8 units
of the estimated slope mean and 1.82 units of the quadratic means were added to the
intercept mean (equation 3).
Table 4 summarizes the fit statistics for the fitted growth models for ANH (model
I.a), GD (model II.a), and SA (model III.a). Fit indices indicated adequate model fit for
ANH (2 / df = 1.77, TLI = 0.996, RMSEA = 0.065; see Table 4 model I.a.) and for SA
(2 / df = 1.68, TLI = 0.997, RMSEA = 0.062; see Table 4 model II.a.).
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Table 4
Fit Statistics for Growth Models Assessing Change Trajectories in Anhedonia (ANH),
General Distress (GD), and Somatic Anxiety (SA) Across Three Time Points (intake,
week 8, and week 16); N = 181 for Each Model
Model 2 df 2 /
df
p TLI RMSEA
estimate
RMSEA
90% CI
Anhedonia
I.a. Growth model without
predictor
42.53 24 1.77 0.011 0.996 0.065 0.031- 0.097
I.b. Growth model with
treatment as predictor
49.84 30 1.66 0.013 0.996 0.061 0.028- 0.090
General Distress
II.a. Growth model without
predictor
52.26 24 2.18 0.001 0.994 0.081 0.051- 0.111
II.b. Growth model with
treatment as predictor
60.04 30 2.00 0.001 0.994 0.075 0.047- 0.102
Somatic Anxiety
III.a. Growth model without
predictor
40.40 24 1.68 0.019 0.997 0.062 0.025- 0.094
III.b. Growth model with
treatment as predictor
44.62 30 1.49 0.042 0.997 0.052 0.010- 0.082
Note. 2 = chi-square test for model fit, df = degrees of freedom, TLI = Tucker-Lewis Index,
RMSEA = root mean squared error of approximation, CI = Confidence Interval.
For GD, model fit was questionable (2 / df = 2.18, TLI = 0.994, RMSEA = 0.081; see
Table 4 model III.a.), which was likely related to the lack of construct stability noted
above. Given that (in the present form of growth modeling) measurement invariance is
assumed (which may present a misspecification of the growth model for GD), parameter
estimates may be biased (e.g., Tomarken & Waller, 2005). This issue will be addressed
below with regard to the interpretation of significant findings.
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As depicted in Table 5, estimated intercepts of the growth parameters in models I.a.,
II.a., and III.a. were significantly different from zero. The estimated pre-treatment status
was positive and significant (p < 0.001 for all three constructs), indicating that levels in
all three constructs ANH, GD, and SA were significantly different from zero at the time
of intake.
Table 5
Estimated Nonstandardized Parameters from Fitted Growth Models I.a. (ANH), II.a.
(GD), and III.a. (SA) examining Growth Parameters (N = 181 for Each Model)
Estimated growth parameters ANH GD SA
parameter p parameter p parameter p
Estimated average initial status
(intercept)
1.910 *** 1.861 *** 1.747 ***
Estimated variance in initial status 0.002 *** 0.002 *** 0.001 ***
Estimated average rate of change
(per 10 weeks) (slope)
-0.178 *** -0.142 *** -0.070 ***
Estimated variance in rate of change 0.021 *** 0.012 ** 0.003 0.234
Estimated average curvature change
of trajectory (per 10 weeks)
(quadratic)
0.044 *** 0.036 *** 0.021 ***
Estimated variance in average
curvature of change trajectory
0.005 *** 0.003 0.052 0.000 0.581
Note. * p < 0.05, ** p < 0.01, *** p < 0.001
The estimated rate of change was significant and negative (p < 0.001 for all three
constructs), whereas the estimated curvature of change was significant and positive (p <
0.001 for all three constructs), indicating that, on average and for both treatment groups
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combined, ANH, GD, and SA decreased significantly over the course of the study with
more change occurring in the first half than in the second half of treatment.
Before attempting to predict some of the variance of these growth parameters, it
should be established that they had significant interindividual variability. The initial
status in ANH, GD, and SA was found to be highly variable between individuals (for all
three constructs, variance was significantly different from zero, p < 0.001). Variability in
rate of change was found to be significant for ANH (p < 0.001) and for GD (p < 0.01),
but not for SA (p = 0.234). Variability in the curvature of the trajectory was found to be
significant for ANH (p < 0.001), yet just missed significance for GD (p = 0.052) and was
clearly not significant for SA (p = 0.581). It is speculated that there was a “floor effect”
with regard to improvement in SA. This speculation finds some support by the fact that
two of the three parcels for SA, namely HRSA_SA and BAI_SA, started out with
relatively small means compared to the other parcels (M  0.82 at intake, for both parcels
and in both groups, see Table 2) and the variability of these parcels decreased over the
course of treatment (SD ranged from 0.45 to 0.57 at intake and from 0.26 to 0.47 at week
16), which was atypical. This pattern was not the case, however, for the third parcel,
HRSD_SA, which showed comparable means and standard deviations to the other
variables (M  2.06 at intake for both groups; SD ranged from 0.65 to 0.68 at intake and
from 0.87 to 1.00 at week 16). Regardless of the cause of these results, small variability
in change factors makes the successful prediction of them statistically less likely, which
should be kept in mind for the following investigation of predictors of change trajectories
in the construct SA.
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Treatment as Predictor of Change in ANH, GD, and SA
After fitting the basic growth models, a dummy variable representing treatment
(coded 0 for PT and 1 for CT) was included as predictor (depicted in Figure 7).
Treatment effects on average pre-treatment levels in each construct (intercept), average
rate of growth (slope factor), and average curvature of trajectory (quadratic factor) were
estimated. Table 4 summarizes the fit statistics for the models I.b (ANH), II.b (GD), and
III.b (SA). Again, fit was good for ANH (2 / df = 1.66, p < 0.05, TLI = 0.996, RMSEA
= 0.061) and for SA (2 / df = 1.49 p < 0.05, TLI = 0.997, RMSEA = 0.062), whereas
caution remains warranted with regard to construct GD (2 / df = 2.00, p < 0.005, TLI =
0.994, RMSEA = 0.075). Table 6 summarizes the parameters (and significance levels)
estimating treatment effects on the second-order growth factors.
Table 6
Estimated Nonstandardized and Standardized Parameters from the Fitted Growth
Models I.b. (ANH), II.b. (GD), and III.b. (SA), examining Treatment Effects on Change
Trajectories over the Course of Treatment (N = 181 for Each Model)
Estimated treatment
effects on growth
trajectories
ANH
(from model I.b)
GD
(from model II.b)
SA
(from model III.b)
Parameter
(standardized)
p Parameter
(standardized)
p Parameter
(standardized)
p
Effect of treatment on
initial status
- .007
(-.075)
.478 .006
(.066)
.576 .016
(.226)
*
Effect of treatment on
rate of change
.056
(.180)
.063 .100
(.432)
*** .025
(.237)
.181
Effect of treatment on
curvature of change
trajectory
-.024
(-.162)
.112 -.049
(-.458)
*** -.019
(-.462)
*
Note. Significance levels were derived from the two-tailed Wald test assessing the likelihood for
the parameter to be no different from zero. * p < 0.05, *** p < 0.001.
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Figure 8 displays the growth trajectories based on growth parameter estimates derived
from models I.b, II.b, and III.b. The trajectories are therefore based on log-transformed
data. However, growth trajectories based on non-transformed were computed for
comparison and were found highly similar. Presented trajectories are therefore fairly
consistent with estimated patterns of change in the non-transformed latent constructs.
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Figure 8. Estimated Average Growth Trajectories of Latent Constructs Anhedonia, General
Distress, and Somatic Anxiety Comparing the Two Treatment Conditions, Pharmacotherapy (PT)
and Cognitive Behavior Therapy (CBT). Parameter estimates were derived from models I.b.
(Anhedonia), II.b. (General Distress), and III.b. (Somatic Anxiety).
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No between-group differences were expected for initial levels in the constructs as
patients were randomized to the treatment groups. Consistent with this expectation, no
treatment effect was found for pre-treatment levels in ANH (Table 6, model I.b). Further,
no significant treatment effects were found with regard to rate or curvature of change for
ANH indicating that groups did not differ with regard to pattern of change in ANH over
the course of treatment. There was a tendency for a higher rate of decrease in the PT than
in the CBT condition, yet the difference did not reach significance (Table 6, model I.b,
p = 0.063).
No treatment group differences in initial GD were found (Table 6, model II.b).
Unlike for ANH, however, there was a highly significant treatment effect on both, the
slope and the quadratic factor in GD (Table 6, model II.b, p < 0.001 in both cases).
Together, this suggests a different pattern of change in GD for the two treatment
conditions. As can be seen in Figure 8, GD decreased more rapidly in the PT condition
than in the CBT condition. In fact, in the PT condition, most of the change in GD
occurred within the first eight weeks of treatment while for CBT, the decrease in GD was
more evenly distributed over the 16 weeks of treatment. Again, caution is warranted in
the interpretation of these significant findings given the questionable model fit for GD,
which will be addressed below.
For SA, surprisingly, treatment significantly predicted the intercept factor suggesting
that the CBT group had higher pre-treatment levels on SA than the PT group (Table 6,
model III.b, p < 0.5). Unlike for GD, no significant treatment differences were found for
the rate of change in SA. Statistically, this result in not surprising given the lack of
interindividual variability for rate of change in SA reported above. Yet, there was some
weak evidence for a between-group difference in the pattern of change in SA based on
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the significant effect of treatment on the quadratic factor (Table 6, model III.b., p < 0.5).
As can be seen in Figure 8, in the PT group virtually all change in SA occurred within the
first half of treatment, whereas change in the CBT group change was more gradual and
evenly distributed across the entire treatment period.
Comorbid Anxiety Disorders as Predictors of Pre-treatment ANH, GD, and SA
Diagnostic status was added as predictor to the basic growth models, I.a, II.a, and
III.a, in order to investigate effects of pre-treatment comorbid anxiety on initial status and
change trajectories of ANH, GD and SA. The following comorbid diagnostic categories,
which included full and subthreshold diagnoses, were investigated: (1) presence of any
comorbid Axis I disorders, (2) presence of any anxiety disorder, (3) OCD, (4) panic
disorder (with or without agoraphobia), (5) GAD, (6) social phobia, (7) specific phobia,
(8) PTSD, and for comparison (9) any eating disorder. Each of these categories was
tested as single predictor of the growth parameters. Otherwise, latent growth models
were equivalent to I.b, II.b, and III.b.
A priori hypotheses existed with regard to the effect of pre-treatment diagnostic
categories on the intake levels of ANH, GD, and SA; analyses testing potential effects of
pre-treatment diagnostic categories on change trajectories were exploratory in nature. In
addition to the standard significance criterion of  = 0.05 (applied to all analyses), a
Bonferroni corrected significance level of  = 0.05 / 9 = 0.006 was considered for the test
of priori hypotheses in order to adjust for the fact that multiple non-orthogonal tests were
performed on the same data. Estimates for the parameters of the fitted growth models
examining effects of pre-treatment comorbid diagnoses on the growth trajectories of
ANH, GD, and SA and their significance levels are summarized in Table 7.
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Table 7
Estimated Standardized Parameters from the Fitted Growth Models examining Pre-
treatment Diagnostic Status as Predictor of Change Trajectories (total N = 181 for Each
Model)
Estimated effects of pre-treatment comorbid
diagnoses on growth trajectories
ANH GD SA
Parameter p Parameter p Parameter p
Any comorbid Axis I diagnosis (n = 112)
Effect on initial status -.036 .741 .255 * .055 .619
Effect on rate of change .007 .944 -.132 .265 -.169 .334
Effect on curvature of change trajectory -.023 .822 .086 .501 .181 .429
Any Anxiety Diagnosis (n = 88)
Effect on initial status -.073 .496 .381 *** .179 .103
Effect on rate of change -.029 .769 -.038 .752 -.093 .594
Effect on curvature of change trajectory .043 .681 -.008 .952 .098 .662
OCD (n = 5)
Effect on initial status .001 .990 .296 * .132 .249
Effect on rate of change .204 * .084 .514 .286 .136
Effect on curvature of change trajectory -.163 .115 -.024 .865 -.223 .430
Panic Disorder (n = 16)
Effect on initial status -.196 .072 .170 .137 .081 .464
Effect on rate of change -.161 .108 -.160 .182 -.104 .552
Effect on curvature of change trajectory .162 .120 .150 .248 .049 .832
GAD (n = 21)
Effect on initial status -.011 .922 .289 ** .267 *
Effect on rate of change -.207 * -.268 * -.225 .144
Effect on curvature of change trajectory .203 .050 .248 * .158 .383
Social Phobia (n = 43)
Effect on initial status -.002 .986 .250 * .062 .578
Effect on rate of change .180 .066 .270 * .000 1.000
Effect on curvature of change trajectory -.176 .087 -.294 * .137 .566
Specific Phobia (n = 28)
Effect on initial status .033 .755 .245 * .326 **
Effect on rate of change .076 .444 -.017 .890 -.111 .514
Effect on curvature of change trajectory -.042 .688 -.014 .913 .103 .636
PTSD (n = 23)
Effect on initial status -.108 .304 .095 .421 .115 .301
Effect on rate of change .085 .387 .260 * .079 .664
Effect on curvature of change trajectory .015 .887 -.237 .086 -.036 .881
Eating Disorder (n = 22)
Effect on initial status .029 .786 -.059 .612 .015 .891
Effect on rate of change .045 .653 .105 .393 .038 .830
Effect on curvature of change trajectory -.067 .518 -.139 .301 -.075 .748
Note. Significance levels were derived from the two-tailed Wald test and indicate the likelihood
for the parameter to equal zero. * p < 0.05, ** p < 0.01, *** p < 0.001, significant estimates are
in bold. Of the significant estimates, the only effects reaching significance according the to
Bonferroni-corrected significance criterion of  = 0.006 were the effect of “Any Comorbid
Anxiety Diagnosis” on initial status of GD and “Specific Phobia” on initial status of SA.
64
None of the diagnostic categories (including all individual anxiety disorders, the
presence of any comorbid Axis I disorder, and the presence of any eating disorder) was
predictive of pre-treatment levels of ANH (Table 7, p > 0.304 for all categories except
panic disorder). In fact, the only effect that approached significance was opposite from
what might be expected: the presence of comorbid panic disorder was associated with
lower pre-treatment levels of ANH (p = 0.072).
In contrast to ANH, the presence of comorbid anxiety disorders was more
consistently associated with a higher pre-treatment level of GD. Using the more lenient
criterion of  = 0.05, significant predictors included OCD (p < 0.05), GAD (p < 0.01),
social phobia (p < 0.05), and specific phobia (p < 0.05). Yet, neither panic disorder nor
PTSD significantly predicted pre-treatment level of GD (p = 0.137 and p = 0.421,
respectively). In addition, the presence of any anxiety disorder was strongly associated
with higher pre-treatment GD (p < 0.001). The presence of any comorbid Axis I disorder
was also (albeit less strongly) associated with higher pre-treatment levels of GD (p <
0.05); comorbid eating disorders were not associated with pre-treatment GD (p = 0.612).
Higher pre-treatment levels of SA were found in individuals with comorbid GAD (p <
0.05) and with comorbid specific phobia (p < 0.005) and none of the other diagnostic
categories. The only effects reaching the more stringent Bonferroni-corrected criterion of
 = 0.006 included the effect of the presence of any comorbid anxiety diagnosis on the
initial status of GD and the effect of comorbid specific phobia on the initial status of SA.
Growth trajectories of ANH, GD, and SA by pre-treatment diagnostic status are
displayed in Figure 9. Post-hoc exploratory analyses of change trajectories suggested
that a smaller rate of change in ANH was predicted by only one of the comorbid anxiety
disorders, namely OCD (p < 0.05). Interestingly, the presence of pre-treatment GAD was
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associated with slightly more change in ANH over the course of treatment (p < 0.05).
Individuals with comorbid GAD improved faster in the first eight weeks of treatment and
continued to improve at about the same rate as those without comorbid GAD during the
second eight weeks of treatment, leading to differences in patterns of change, which
barely missed significance (p = 0.050).
With regard to GD, differences in change trajectories were predicted by GAD, social
phobia, and PTSD (p < 0.05). For GAD and social phobia, differences in curvature of
change trajectories were also found (p < 0.05). Pre-treatment diagnoses of social phobia
and of PTSD were associated with less change in GD over the course of treatment.
Furthermore, unlike change trajectories for individuals without social phobia which (on
average) indicated most of the change in GD to occur within the first eight weeks of
treatment, change trajectories for individuals with social phobia were (on average) more
linear. Similarly to ANH, GD actually changed more on average for those individuals
who endorsed pre-treatment GAD than for those who did not. However, GD decreased
faster for individuals with comorbid GAD only in the first (and not in the second) half of
the treatment period. Thus, there was a group differences in GD change trajectories, i.e.,
trajectories were more curved for the GAD group (p < 0.05). No significant predictors
were identified for pattern of change in SA (effects on slope factor: p > 0.136, effect on
quadratic factor: p > 0.383, for all diagnostic categories).
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Figure 9. Estimated Average Growth Trajectories of Latent Constructs Anhedonia, General
Distress, and Somatic Anxiety Contrasting Groups With versus Without Pre-treatment Comorbid
Diagnoses. OCD = comorbid obsessive compulsive disorder, panic disorder = comorbid panic
disorder with or without agoraphobia.
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Figure 9, continued. GAD = comorbid generalized anxiety disorder, social phobia = comorbid
social phobia.
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Figure 9, continued. Specific phobia = comorbid specific phobia, PTSD = comorbid post-
traumatic stress disorder.
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CHAPTER V
DISCUSSION
Summary of Findings
The main aim of this study was to use the tripartite model of anxiety and depression
as a theoretical basis for examining change in symptom clusters in a depressed outpatient
sample over the course of treatment. Specific goals included (a) the test of a three-factor
structure consistent with the tripartite model in the present data set, (b) the investigation
of treatment effects (PT versus CBT) on the pattern of change in the three latent
constructs, ANH, GD, and SA, over the course of treatment, and (c) an evaluation of pre-
treatment comorbid anxiety diagnoses as predictors of initial levels and change in ANH,
GD, and SA.
Three – factor structure. As hypothesized in H 1, a three factor-structure consistent
with the tripartite model dimensions provided excellent fit for the present data set.
Results of the CFA were consistent with previous theoretical and empirical findings
providing support for the tripartite model structure (e.g., Clark, Steer, & Beck, 1994;
Joiner, 1996; Joiner, Catanzaro, & Laurent, 1996; Watson et al., 1995a, b; 1996). Two
plausible alternative models were evaluated, a four-factor structure similar to that
proposed by Burns & Eidelson (1998), and a two-factor structure with factors
representing Anxiety and Depression, respectively. Neither was found superior to the
three-factor model. The four-factor model provided good fit for the data as well, but
parameter estimates produced by this model were inconsistent with theoretical
assumptions, which made the model difficult to interpret. The two-factor model provided
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poor fit for the data and proved significantly inferior to the four-factor model, which
itself showed a non-significant trend to be inferior to the three-factor model. A reduced
three-factor model with a narrower and temporally more stable GD factor also provided
an excellent fit for the data. Yet, as mentioned earlier, many other theoretical models
may be plausible and provide good fit for the data as well.
Both three-factor models indicated highly significant positive correlations among the
latent constructs, which were slightly smaller in the reduced model. Correlations
between GD and SA (.71 in both cases) were similar to those reported in previous studies
(ranging from .50 to .71) involving non-clinical (e.g., Joiner, 1996; Watson at al., 1995b)
and patient populations (e.g., Brown et al., 1998; Joiner et al., 1999; Lambert et al., 2004;
Watson at al., 1995b). Present correlations between ANH and GD (.68 and .78) and
between ANH and SA (.58 and .61) fell in the high range of previous reports for
correlations between ANH and GD (ranging from .49 to .84) and between ANH and SA
(.23 to .72) involving non-clinical (e.g., Joiner, 1996; Lambert et al., 2004; Watson, et al.,
1995b) and clinical populations (e.g., Brown et al., 1998; Burns & Eidelson, 1998;
Lambert et al., 2004; Watson, et al., 1995b). Based to previous studies, correlations
between factors representing the tripartite components appear to be higher in clinical as
opposed to non-clinical populations. The present study involved a more severely
depressed sample than most previous studies on this subject. All participants met criteria
for major depressive disorder with fairly severe and chronic symptoms. Even though the
confirmatory factor analysis was based on post-treatment data of the current sample,
residual levels of psychopathology were still present. One possible interpretation of the
results is that symptom clusters are more linked in this population even after treatment.
However, other factors which may have contributed to discrepancies among studies may
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include the selection of manifest variables (availability of measures and selection of
items) and differences in data analytic techniques (e.g., the present model did not allow
for cross-loadings).
Tests of construct invariance revealed that ANH, GD, and SA were sufficiently stable
across time when tested separately in each treatment group. ANH, and SA were also
sufficiently stable across treatment groups, whereas GD was not stable across treatment
groups. Variability in the measurement of GD, statistically manifested in the somewhat
different patterns of factor loadings across time and groups, suggests that GD may
represent slightly different theoretical constructs in the two treatment groups at one or
more time points. Although these findings may be a statistical artifact of uneven and
relatively small sample sizes or other causes, caution for the interpretation of growth
curve modeling, especially with regard the effects of predictors, is warranted.
Treatment differences in change curves of ANH, GD, and SA. Consistent with H 2,
both treatments led to significant improvement in ANH, GD, and SA suggesting that both
PT and CBT had benefit for all three symptom clusters. Given that the present analyses
did not include the placebo condition, significant changes with treatment (i.e. slopes of
trajectories significantly different from zero) or differences between PT and CBT do not
by themselves imply the superiority of either treatment to placebo. For present purposes
of investigating differential effects of PT and CBT on symptom change, a comparison to
placebo is not required. Yet, it may be of interest in this context, that previous analyses
on the present data have shown both PT and CBT to be superior to placebo treatment
with regard to using the 17-item version of the HRSD (DeRubeis et al., 2005). Given
that the currently investigated symptom dimensions are in part based on symptoms of the
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HRSD, there is reason to speculate (yet not assume) that this superiority of both PT and
CBT over placebo would hold for one or more of the symptom dimensions.
With regard to treatment differences, GD was found to improve significantly faster
and at a higher rate with PT than with CBT, which is consistent with H 3. On a
cautionary note, the fact that GD was not invariant across groups makes an interpretation
of these findings more difficult as a less than ideal model fit may have biased parameter
estimates including treatment effect. Specifically, this may have increased the
probability of discovering statistically significant treatment effects. Yet, given the highly
significant finding of group differences, there is reason to belief that this was, at least in
part, due to an advantage of PT over CBT with regard to improving GD.
In general, this finding is consistent with previous reports of serotonergic agents to be
particularly effective in treating symptoms of general distress and anxiety (Bodkin et al.,
1997; Knutson et al., 1998; Shelton and Tomarken, 2001). Indeed, our results suggest
that in a severely depressed population, the SSRI paroxetine may improve GD more
rapidly than CBT. With PT, most change in GD occurred (on average) within the first
eight weeks of treatment, whereas GD (on average) continued to decrease at a fairly
steady rate with CBT over the entire 16 weeks of treatment. With regard to PT, these
findings are consistent with previous reports of SSRIs most potently affecting GD
symptoms within the first six weeks of treatment (e.g., Boyer et al., 2000; Knutson et al.,
1998; Ravindran et al., 1997; Sheehan et al., 1992; Lammers, Diaz, Schwartz & Sokoloff,
2000).
On the other hand, results do not suggest the same advantage for PT compared to
CBT in the treatment of symptoms consistent with ANH, which provides support for the
distinctiveness of the constructs GD and ANH. No statistically significant between-
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group differences were found in change of ANH with regard to either rate or pattern of
change. Unfortunately, this null finding does not provide strong support for either H 4a
or H 4b and is open to a large number of possible interpretations. Clearly, a relation
between ANH and GD is fairly well established based on consistently high correlations
reported in the literature (as mentioned above) and has been found in the present data as
evidenced by the moderately high correlations between the latent constructs of ANH and
GD. Also, the finding that both symptom clusters improved at fairly similar rates
provides support for the effectiveness of PT and CBT in the treatment of both GD and
ANH. There was a non-significant trend for ANH to improve at a greater rate with PT
than with CBT, which suggests some support for H 4b proposing equivalent patterns of
change for GD and ANH. However, the finding that the treatment effect on rate and
pattern of change in ANH was far less pronounced than in GD and did not reach
significance, also provides some support for H 4a, which proposed that PT would not be
superior to CBT in the treatment of ANH. This differential pattern of treatment effects
on ANH as opposed to GD provides some support for the distinctiveness of these
symptom dimensions and their differential response to treatment.
Given that differential change curves between constructs was not contrasted
statistically in the present analyses, it cannot be determined from the present data,
whether the lack of treatment group differences in the treatment of ANH is mostly related
to (a) the relatively lower effectiveness of paroxetine with regard to ANH, (b) the
emphasis on behavioral activation in the early sessions of CBT, or (c) both, cannot be
decided in the present study. Interpretation (a) would be consistent with previous reports
of the lower and/or slower effectiveness of SSRI’s found in the treatment on ANH
symptoms (e.g., Bodkin et al., 1997; Boyer et al., 2000) rather than studies which failed
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to find differential treatment effects (e.g., Dichter et al., 2005). Clearly, more research is
needed to identify the various factors contributing to effectiveness, as well as the lack
thereof, in the treatment of ANH.
The pattern of improvement in SA, expected to closely follow the pattern of GD (H
5), was only partly congruent with expectations. Similarly to GD, most change in SA
occurred within the first eight weeks of treatment in the PT condition, whereas change
occurred more gradually with CBT. Contrary to H 5, however, the average rate of
change across the entire course of treatment (slope of trajectory) did not differ for the two
treatment groups. Also unexpectedly (and likely due to chance), individuals in the CBT
condition started out with significantly higher levels of SA than individuals in the PT
condition. Although findings might provide some support for the distinctiveness of GD
and SA as they seem to differ with regard to treatment effects, it is likely that individuals
reached a “floor” with regard to improvement in SA at week 16. In fact, in PT this floor
may have been reached already at week 8. This latter speculation finds support by the
findings of relatively small, but highly variable, initial levels of SA together with a
decrease in variability in this construct over time.
The effect of comorbid anxiety disorders at intake on the change curves of ANH,
GD, and SA over the course of treatment. Consistent with the tripartite model and the
expectation expressed in H 6, none of the comorbid anxiety disorders at intake was
associated with a difference in pre-treatment levels in ANH. In contrast to ANH and
largely consistent with H 7, most pre-treatment comorbid anxiety disorder diagnoses,
namely OCD, GAD, social phobia, and specific phobia, predicted a higher pre-treatment
levels of GD. Interestingly, panic disorder and PTSD were exceptions to this finding.
The presence of any anxiety disorder diagnosis was strongly associated with higher pre-
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treatment levels of GD. With the more stringent Bonferroni-corrected criterion for
significance, the presence of any anxiety disorder diagnosis (yet none of the individual
diagnostic categories) predicted higher pre-treatment GD. In comparison, the presence of
pre-treatment eating disorders was not associated with elevated levels of GD. Taken
together, these findings are consistent with previous findings of GD being shared by both
depression and anxiety disorders, and ANH being specific to depression (e.g., Brown et
al., 1998; Chorpita, 2002; Watson et al., 1988), and provide at least some support for an
additive quality of GD in comorbid conditions which are both individually associated
with GD.
Contrary to prediction H 8, comorbid panic disorder neither predicted higher levels of
pre-treatment SA nor change in SA with treatment. Instead, pre-treatment comorbid
GAD and specific phobia were the only diagnostic categories found to predict higher
levels of SA at intake; only the effect for specific phobia reached significance after
Bonferroni-correction. Although the tripartite model does not make direct predictions for
comorbid conditions, the present findings are considered to be rather inconsistent with
the theory of the tripartite model, which stipulates SA to be the unique component of
anxiety (as compared to depression). Based on the model, higher levels of SA would be
expected to be present before treatment in individuals with comorbid anxiety conditions.
In addition, the lack of association of panic disorder with SA is also not consistent
with previous studies, which found SA to be positively correlated with panic disorder
(Brown et al., 1998; Chorpita. 2002). One plausible explanation of the discrepancy
between the theoretical foundation of the tripartite model and empirical findings, which
frequently fail to identify a relation between SA and most anxiety disorders may be that
SA is present and/or reported only when individuals are confronted with anxiety-
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provoking stimuli. Thus, when avoided successfully, SA may not differ significantly
between individuals with and without a specific anxiety disorder. It remains open for
speculation, however, why significant pre-treatment elevations in SA were found in
individuals with comorbid GAD and specific phobia.
As predicted in H 9, the presence of any pre-treatment comorbid Axis I diagnosis was
also associated with higher pre-treatment GD (albeit less strongly than the presence of
comorbid anxiety diagnosis and not significant after Bonferroni correction), yet was not
associated with pre-treatment ANH or SA. This provides some support for the idea that
GD may be common in psychopathology other than depression and anxiety disorders as
well (Shelton & Tomarken, 2001).
Remarkably, exploratory analyses (using the more lenient criterion of alpha = .05)
revealed that diagnostic group differentially predicted change in the symptom
dimensions. Different comorbid diagnostic conditions emerged as predictors of change
in GD versus ANH and none of the diagnostic categories was associated with change in
SA. Pre-treatment comorbid social phobia and PTSD were both associated with smaller
rates of change in GD. For individuals with comorbid social phobia, the disadvantage
was more pronounced in the first eight weeks of treatment. These findings suggest that
social phobia and PTSD are negative predictors of change in GD regardless of initial
levels. In addition, the presence of pre-treatment comorbid OCD predicted less
improvement in ANH over the course of treatment. The presence of comorbid OCD at
intake can therefore be viewed as negative predictor of change in ANH. Although the
simultaneous prediction of growth by both pre-treatment diagnostic status and treatment
group was not pursued in the present study, it is likely that the effects of comorbid
conditions on change in symptom dimensions differed for the two treatment groups.
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Curiously, GAD emerged as a positive predictor of change in both GD and ANH.
The presence of pre-treatment GAD, though expectedly associated with higher levels of
GD at intake, was also associated with more and more rapid reduction in GD. Pre-
treatment GAD very similarly predicted more change in ANH, though the effects were
less pronounced (in fact, the effect on curvature missed significance at p = 0.050).
Visual inspection of change curves revealed that comorbid GAD was a positive predictor
of change in GD and ANH only in the PT condition and not in the CBT condition. As
GD may play a particularly central role in patients reporting both depression and GAD
symptoms (Zinbarg et al., 1994), this finding might be seen as yet another instantiation of
the efficiency of PT in reducing GD symptoms. The relative greater reduction in ANH
for this comorbid group was more surprising and may argue for the link between GD and
ANH.
In sum, most pre-treatment comorbid anxiety disorders predicted higher levels of GD
at intake, yet none of the pre-treatment comorbid anxiety disorders predicted pre-
treatment ANH, and only GAD and specific phobia predicted higher levels of SA at
intake. Findings are largely consistent with the tripartite model in that comorbid anxiety
disorders were associated with increased GD, yet not ANH. On the other hand, in this
severely depressed sample, comorbid anxiety disorders were not consistently found to be
associated with SA. If replicated, the discovery of comorbid conditions as negative (or
positive) predictors of change in specific symptom clusters has important relevance for
treatment planning.
Limitations and Future Directions
There were several limitations which restrict the generalizability of the findings.
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First, depression in the present sample was fairly severe, either highly recurrent or
chronic, and started for many participants before adulthood. These characteristics may
have decreased the likelihood of detecting certain effects such as differences between
diagnostic groups with regard symptom dimensions (both, initial levels and change
trajectories). The main reason for this is restricted variability of symptom levels
compared to less depressed populations. Specifically, when GD and ANH are high
throughout the entire sample, comorbid conditions can only add relatively little to these
dimensions before reaching a “ceiling”. For this reason, differences between comorbid
diagnostic categories with regard to these symptom dimensions might be more
pronounced in a less severely depressed population.
Second, given the requirement of relatively large sample sizes for second-order LGM
(e.g., Muthén & Curran, 1997; MacCallum, Browne, & Sugawara, 1996), it is possible
that the (uneven) sample sizes of 62 (CBT) and 119 (PT) did not provide enough power
for certain parameter estimates to reach significance and contributed to the instability of
the construct GD across groups. Also, despite the high rate of comorbid anxiety
disorders (48.6%), the prevalence of individual anxiety disorders was still relatively
small. For this reason, subthreshold levels of comorbid conditions were included, which
could have diminished group effects. Even after this inclusion, the number of individuals
with comorbid OCD was small (n = 5), which on the one hand leaves little power to
detect small effects, and on the other hand lead to effects which are not generalizable.
Nonetheless, the differential effects of pre-treatment diagnostic status on initial levels of
and change in the different symptom clusters were encouraging and should be replicated
in broader samples including less depressed individuals.
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Third, the assessment of the latent constructs was limited by a number of factors. An
attempt was made to match measurement methods across constructs, but due to
availability of items, this was not entirely possible. For example, a larger number of
items across a larger variety of measures were available to assess the construct GD than
were available for the assessment of the constructs ANH and SA. The relative lack of
items representing ANH was indicative of a more general under-representation of items
representing ANH as compared to GD in depression measures, discussed earlier. Also,
only three time points were used for the current analyses. They were chosen because all
measures of interest were administered at these time points. Clearly, the optimal
frequency of symptom assessments is itself subject to investigation. However, more
frequent assessment would allow for more precise modeling of growth trajectories. In
addition to weekly average ratings, range and variability of ANH, GD, and SA across
time may contain valuable information and should be explored in future studies as well.
With regard to SA, the range and frequency of high SA periods (in addition to the
assessment of weekly averages) may capture additional aspects of treatment effects.
Fourth, even though all participants in the PT condition received paroxetine as their
primary medication during the first eight weeks of treatment, there was flexibility with
regard to augmentation strategies after this period. Therefore, findings regarding the
second half of treatment cannot be solely related to the effects of paroxetine.
Interestingly, however, significant treatment effects (i.e., more improvement in GD and
more curvilinear change trajectories in both GD and SA) were due to the relative
advantage of PT over CBT within the first eight weeks of treatment making the
implication of paroxetine in these effects rather likely.
Fifth, in the present study the constructs ANH, GD, and SA were modeled separately
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and change trajectories in the three symptom dimensions were not compared statistically.
It would be extremely useful to directly compare the rate of change in two (or all three)
symptom dimensions as a function of treatment condition. LGM provides a particularly
helpful tool to model change in different constructs simultaneously (i.e. multivariate)
across time. This type of analysis can help address questions such as whether (a) one or
both treatment(s) affected one symptom dimension more than another and (b) whether
change in one symptom dimension preceded or even mediated change in another
symptom dimension.
Finally, present analyses do not provide any insight into mechanisms underlying the
differential treatment effects. Interindividual differences in symptom change trajectories
may have been mediated by any number of factors. It is impossible to discern the various
variables in the pharmacological and the cognitive-behavioral treatment which facilitated
(or hindered) symptoms reduction. The use of dual differentiation desings, i.e.
contrasting two treatments known to involve different mechanisms and hypothesized to
show opposite patterns in the reduction of symptom groups (e.g., Dichter et al., 2005) is
particularly valuable in this context and should also be applied to psychotherapy research.
For instance, treatment modalities and techniques should be compared with regard to
differential effects on these symptom dimensions.
Conclusion
The CPT II data set provided a unique opportunity to test the tripartite model
structure in the treatment of depression. The tripartite model of anxiety and depression
(Watson & Clark, 1991), particularly the distinction between symptoms of NA/GD
versus symptoms of low PA/ANH, has found support from several different research
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areas. Although there have been a growing number of empirical studies examining the
validity of the tripartite model regarding the structure of anxiety and depression
symptoms, to the knowledge of the author, this is the first study to use this model as a
heuristic to compare the efficacy of PT versus CBT in the treatment of depression. The
present study was aimed at investigating differential treatment effects of PT versus CBT
on the change trajectories of the three dimensions, GD, ANH, and SA. The SSRI
paroxetine was found to have relative advantage over CBT in the early treatment of GD
symptoms, but not in the treatment of ANH symptoms. Also, a differential treatment
effect on the pattern of change in SA was found reflecting the fact that almost all change
with PT occurred within the first eight weeks of treatment, while change with CBT
occurred more gradually over the entire sixteen weeks of therapy. Further, even in this
fairly severe sample, the presence of any comorbid Axis I condition, but comorbid
anxiety disorders in particular, was associated with higher levels of GD (and to a lesser
degree SA), but not ANH.
In sum, results provide further support for the distinctiveness of the investigated
symptom clusters and therefore for the validity of the tripartite model. Findings also
argue for the potential usefulness of the tripartite model as a heuristic for the selection of
treatment strategies and for the development of treatment for depression in general.
Further research should focus on differential mechanisms by which PT and CBT effect
change in these symptom dimensions.
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APPENDIX A
HAMILTON RATING SCALE FOR DEPRESSION (HRSD)
OVERVIEW: I'd like to ask you some questions about the past week.
1. DEPRESSED MOOD
DEPRESSED MOOD (sad, hopeless, helpless,
worthless)
What's your mood been like this past week? (0) absent
Have you been feeling down or depressed? (1) mild: these feeling states indicated only on
questioning and are not the predominant
mood state; feels depressed no more than
two days or only intermittently
Sad? Hopeless? Numb? (2) moderate: these feeling states
spontaneously reported; feels depressed
more days than not (i.e., the predominant
mood state)
Have you been crying at all? (3) marked: communicated feeling states non-
verbally, i.e., facial expression, posture,
voice tendency to weep; some functional
impairment
In the last week, how often have you felt this way
(PATIENT'S OWN EQUIVALENT)? Every day?
All day?
(4) severe: patient reports VIRTUALLY
ONLY these feeling states in his
spontaneous verbal and non-verbal
communication; severe functional
impairment
2. FEELINGS OF GUILT
Have you been especially critical of yourself this
past week, feeling you've done things wrong, or let
others
FEELINGS OF GUILT:
down? IF YES: What have your thoughts been? (0) absent
Have you been feeling guilty about anything that
you've done or not done?
(1) self-reproach (whether or not there has been
wrongdoing), feels she/he has let people
down
Have you thought that you've brought your troubles
on yourself in some way?
(2) ideas of guilt spontaneously expressed
How often have you had these thoughts? Do these
thoughts ever repeat themselves? How much have
they bothered you? Are these thoughts
uncontrollable?
--Do you think you're being punished for something
you did?
-- Do these thoughts ever sound like they come from
the outside, like hearing someone else's voice? If so,
whose voice is it?
(3) Present illness is a punishment; or repeated
intrusive guilty thoughts (i.e., ruminations)
over past errors or sinful deeds
(4) hears accusatory or denunciatory voices
and/or experiences threatening visual
hallucinations; delusions of guilt
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APPENDIX A, continued
3. SUICIDE
This past week, have you had any thoughts that life
is not worth living, or that you'd be better off dead?
SUICIDE:
What about having thoughts of hurting or even
killing yourself?
(0) absent
(1) feels life is not worth living
IF YES: What have you thought about?
Have you actually done anything to hurt yourself?
(2) wishes she/he were dead or thoughts of
possible death to self (other than suicidal)
(3) suicidal ideas or specific suicide plan
(4) attempts at suicide
SUM OF ITEMS 1, 2, AND 3: _________________
“Typical” Sleep Items
4. INSOMNIA EARLY
How have you been sleeping over the last week?
How many hours have you been getting?
INSOMNIA EARLY:
Have you had any trouble falling asleep at the
beginning of the night?
(0) no difficulty falling asleep
(Right after you go to bed, how long has it been
taking you to fall asleep?)
(1) mild and/or infrequent: less than 30
minutes most nights, or if longer no more
than twice during the past week
How many nights this week have you had trouble
falling asleep?
(2) definite and severe, more than 30 minutes
on most nights
5. INSOMNIA MIDDLE
During the past week, have you been waking up in
the middle of the night?
IF YES: how many nights? How often do you
awaken?
INSOMNIA MIDDLE:
Do you get out of bed? What do you do? (Only to go
to the bathroom?)
(0) no difficulty
When you get back in bed, are you able to fall right
back asleep?
(1) mild and/or infrequent: complains of being
restless and disturbed some nights
Have you felt your sleeping has been restless or
disturbed some nights?
(2) definite and severe: waking most every
night (except for purposes of voiding);
difficulty getting back to sleep (i.e., more
than 30 minutes most nights) or multiple
brief awakenings each night
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APPENDIX A, continued
6. INSOMNIA LATE
What time have you been waking up in the morning
for the last time, this past week?
INSOMNIA LATE:
Is this earlier than you would like? (0) no difficulty
IF EARLY: Is that with an alarm clock, or do you
just wake up by yourself?
(1) mild and/or infrequent: wakes earlier than
usual some mornings (i.e., 30 minutes
earlier than desired) or infrequently (i.e., 1
or 2 mornings)
(2) definite and severe: wakes 1-3 hours before
usual time and is unable to sleep again
Sum of items 4, 5, and 6: ____________
Atypical Sleep Items
4A. HYPERSOMNIA (Retires earlier and/or rises later)
When do you go to bed?
HYPERSOMNIA (Retires earlier and/or rises later
than usual. This does not necessarily mean that
the patient sleeps longer, just spends more time in
bed.)
Is this earlier than usual (when not depressed) for
you?
(0) absent
IF YES: How much earlier? (Weekends?) (1) mild; less than 60 minutes
When do you get up? (2) obvious and definite; goes to bed more than
60 minutes earlier on most nights
Is this later when not depressed? (Weekends?)
5A. HYPERSOMNIA (Oversleeping, sleeping more than usual)
Compare sleep length to euthymic and not to
hypomanic sleep length.
If this cannot be established, use 8 hours.
HYPERSOMNIA (Oversleeping, sleeping more
than usual)
Oversleeping - Have you been sleeping more than
usual this past week?
(0) absent
IF YES: How much more?
(1) mild or infrequent: Oversleeps less than 60
minutes
IF NO: What about weekends?
(2) obvious and definite: Oversleeps more
than 60 minutes most days
Sleep length used: (Circle one)
euthymic 8 hours
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6A. HYPERSOMNIA (Napping - excessive daytime sleepiness)
Do you take naps?
HYPERSOMNIA (Napping. Excessive daytime
sleepiness.)
IF YES: When? How often? How long?
(0) absent
IF NO: How about weekends?
(1) mild or infrequent: naps less than 30
minutes
(2) obvious and definite: sleeps more than 30
minutes most days during naps
Sum of items 4A, 5A, and 6A: ____________
SLEEP DISRUPTION TOTAL SCORE: _____________
(Enter the sum of items 4, 5, and 6;
OR the sum of items 4A, 5A, and 6A, whichever is greater)
7. WORK AND ACTIVITIES
How have you been spending your time this past
week (when not at work)?
WORK AND ACTIVITIES:
Do you have your normal interest in doing (THOSE
THINGS), or do you feel you have to push yourself
to do them?
(0) no difficulty
Are you less interested in things like your job,
spending time with family, friends or hobbies?
Have you decreased or even stopped doing anything?
IF WORKING: Do you feel you are less efficient or
effective at work?
Have you been able to have any fun? How has your
ability to feel enjoyment or pleasure been?
(1) thoughts and feelings of incapacity, or
disinterest related to activities, work or
hobbies; mild and/or intermittent
(2) decreased interest in activity, hobbies or
work most days - either directly reported by
the patient or indirect in listlessness,
indecision and vacillation (feels he/she has
to push self to work or engage in activities)
(3) definite decrease in actual time spent in
activities or decreased productivity due to
depression
(4) Complete loss of interest. Anhedonia.
Stopped working or engaging in routine
activities because of depression
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8. RETARDATION
RATING BASED ON OBSERVATION DURING
INTERVIEW
RETARDATION (slowness of thought and
speech; impaired ability to concentrate; decreased
spontaneous motor activity; postural change -
slumped, stooped):
(0) normal speech and thought
(1) mild: slight flattening of affect, fixity of
expression, or minimal slowing of speech
and/or spontaneous movements
(2) moderate: monotonous voice, delayed in
answering questions, tends to sit motionless
(3) severe: retardation prolongs interview to a
marked degree, slowness of movement and
gait with diminished associated movement
(4) extreme: depressive stupor, interview
impossible
9. AGITATION
RATING BASED ON OBSERVATION DURING
INTERVIEW
AGITATION (restlessness, repetitive "nervous"
mannerisms, frequent posture changes, difficulty
sitting still):
(0) none
(1) mild: fidgety at interview, clenching fists or
side of chair, kicking feet
(2) moderate: wringing hands, biting lips,
pulling hair, gesturing with arms, picking at
hands and clothes
(3) severe: includes features of (2). In
addition, cannot stay in chair during
interview
(4) extreme: hand-wringing, nail biting, hair-
pulling, biting of lips, almost continual
pacing. Patient looks bewildered and
distraught.
SUM OF ITEMS 7, 8, AND 9: _____________
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10. ANXIETY PSYCHIC
Have you been feeling especially anxious, nervous,
tense or irritable, frightened and/or apprehensive this
past week?
ANXIETY PSYCHIC:
(0) no difficulty
Have you had a hard time relaxing this past week?
(1) mild, i.e., intermittent tension or irritability
(2) moderate: worried, tense, anxious or
nervous more often than not; not
incapacitated
Have you been worrying a lot about little
unimportant things, things you wouldn't ordinarily
worry about?
(3) severe: psychic anxiety symptoms most of
the time; anxiety is the predominant mood
state, incapacitated by psychic anxiety
symptoms
IF YES: Like what, for example? (4) fears expressed without questioning
11. ANXIETY SOMATIC
In this past week, have you had any of these physical
symptoms? READ EACH LIST TO THE RIGHT,
PAUSING AFTER EACH THREE FOR REPLY
ANXIETY SOMATIC – physiologic
concomitants of anxiety, such as:
dry mouth, gas, indigestion;
How much have these things been bothering you this
past week? (How bad have they gotten? How much
of the time, or how often, have you had them?)
diarrhea, cramps, belching; nausea, constipation;
heart palpitations, headaches, dizziness;
hyperventilating, sighing;
having to urinate frequently, sweating, trouble
swallowing
(0) absent
DO NOT RATE IF SYMPTOMS ARE
ABSOLUTELY AND UNEQUIVOCALLY
RELATED TO A TRANSIENT MEDICAL
PHENOMENON (I.E., MENSTRUATION, AN
INFECTION, OR ACUTE COCAINE
INTOXICATION)
(1) doubtful or infrequent
(2) mild: reports at least several symptoms,
which are not marked or incapacitating
(3) moderate: greater number and frequency of
symptoms than (2). Accompanied by more
severe subjective distress with some
impairment of normal functioning
(4) severe: symptoms are numerous, persistent
and incapacitating much of the time
12. APPETITE DECREASE
How has your appetite been this past week? DECREASED APPETITE:
(What about compared to your usual appetite?) (0) none
Have you had to force yourself to eat? (1) decreased appetite but eating without
encouragement
Have other people had to urge you to eat? (2) definite decrease; difficulty eating without
urging
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12A. APPETITE INCREASE
Are you definitely eating more than usual? INCREASED APPETITE (Change in appetite
marked by increased food intake)
Have you noticed cravings for specific foods, such as
sweets or chocolates?
(0) absent
(1) mild: minimal or slight increase in appetite;
food craving
(2) obvious: definite and marked increase in
food intake
APPETITE DISTURBANCE SCORE: ______________
(Enter the score for 12 OR 12A, whichever is greater)
SUM OF ITEMS 10 AND 11, PLUS APPETITE DISTURBANCE SCORE: _____________
13. ENERGY
How has your energy been this past week? ENERGY:
Do you tire more easily than usual? If yes how much
of the time?
(0) none
Have you felt fatigued? (1) mild, intermittent, infrequent. Loss of
energy, and fatigue
Do you feel heaviness in your limbs or other parts of
your body? How often do you feel this way? How
much has it affected you?
(2) definitely present most every day;
subjectively experienced as severe
14. LIBIDO
How has your interest in sex been this week? (I'm
not asking you about performance, but about your
interest in sex - how much you think about it.)
SEXUAL SYMPTOMS (such as loss of libido):
(0) absent
Has there been any change in your interest in sex
(from when you were not depressed?)
(1) mild: some decrease in libido, although not
complete or persistent
Is it something you've thought much about? (2) severe: complete absence/loss of sexual
desire
15. HYPOCHONDRIASIS
In the last week, how much have your thoughts been
focused on your physical health or how your body is
working (compared to your normal thinking)?
HYPOCHONDRIASIS:
(0) absent
Do you complain much about how you feel
physically?
(1) mild: some preoccupation with bodily
functions and physical symptoms
Have you found yourself asking for help with things
you could really do your self?
(2) moderate: much attention given to physical
symptoms. Patient expresses thoughts of
organic disease with a tendency to
somaticize.
IF YES: Like what, for example? How often has
that happened?
(3) severe: convictions of organic disease to
explain present condition, e.g. brain tumor
(4) extreme: hypochondriacal delusions often
with guilty association, e.g. rotting inside
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16. LOSS OF WEIGHT
Have you lost any weight since this (DEPRESSION)
began? IF YES: How much?
LOSS OF WEIGHT:
(0) no weight loss or weight loss associated
with dieting
IF NOT SURE: Do you think your clothes are any
looser on you?
(1) probable weight loss associated with present
illness
(2) efinite (according to patient) weight loss,
at least 5 lbs. (2.2 kg) during the episode
16A. WEIGHT GAIN
Have you gained any weight since this
(DEPRESSION) began? IF YES: How much?
WEIGHT GAIN:
(0) no weight gain
IF NOT SURE: Do you think your clothes are any
tighter on you?
(1) probable weight gain associated with
present illness
(2) definite (according to patient) weight gain,
at least 5 lbs. (2.2 kg) during the episode
WEIGHT CHANGE SCORE: _______________
(Enter the score for 16 OR 16A, whichever is greater)
SUM OF ITEMS 13, 14, AND 15, PLUS WEIGHT CHANGE SCORE: _____________
17. INSIGHT
RATING BASED ON OBSERVATION INSIGHT:
Optional probe: What do you think the source of
your current problem is?
(0) acknowledges being depressed and ill OR, if
appropriate, not currently depressed
(1) acknowledges illness but attributes cause to
bad
food, climate, overwork, virus, need for rest,
etc.
(2) denies being ill at all; despite having
definite symptoms
TOTAL 17-ITEM ADJUSTED HAMILTON DEPRESSION SCORE:
_____________
(Add the totals at the bottom of pages 1, 3, 4, 5, 6, and 7 above)
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18. DIURNAL VARIATION
This past week have you been feeling better or worse
at any particular time of day - morning or evening?
DIURNAL VARIATION:
When present, mark the severity and frequency of
the mood variation (if NO diurnal variation, mark
NONE):
IF VARIATION: How much worse do you feel in
the (MORNING OR EVENING)?
(0) no variation OR currently not depressed
(1) mild variation
How many days have you noticed a difference? (2) severe variation
IF UNSURE: A little bit worse or a lot worse? NOTE WHETHER SYMPTOMS ARE WORSE
IN THE MORNING OR EVENING:
_______ worse in the A.M.
_______ worse in the P.M.
19. DEPERSONALIZATION AND DEREALIZATION
In the past week, have you ever suddenly had the
feeling that everything is unreal, or you're in a dream
DEPERSONALIZATION AND
DEREALIZATION (such as feelings of unreality
and nihilistic ideas):
or cut off from other people in some strange way?
Any spacey feelings? (0) absent
(1) mild
IF YES: How bad has that been? How often this
week has that happened?
(2) moderate
(3) severe
(4) incapacitating
20. PARANOID SYMPTOMS
This past week, have you felt that anyone was trying
to give you a hard time or hurt you?
PARANOID SYMPTOMS:
(0) none
IF NO: What about talking about you behind your
back?
(1) mildly suspicious
IF YES: Tell me about that.
(2) more persistent and/or frequent ideas of
reference
(3) delusions of reference and persecution
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21. OBSESSIONAL AND COMPULSIVE SYMPTOMS
In the past week, have there been things you've had
to do over and over again, like checking the locks on
OBSESSIONAL AND COMPULSIVE
SYMPTOMS:
the doors several times, or washing your hands over
and over?
IF YES: Can you give me an example?
(0) absent
(1) mild or intermittent symptoms
Have you had any thoughts that don't make any
sense to you, but that keep running over and over in
your mind? IF YES: Can you give me an example?
(2) severe and/or incapacitating symptoms
22. HELPLESSNESS
Have you had any helpless feelings in the past week? HELPLESSNESS:
Do you feel able or capable to solve your problems? (0) absent
Have you needed someone to guide or reassure you
to get things done?
(1) mild or intermittent; subjective feelings
elicited only by inquiry
(2) moderate: patient volunteers his/her
helpless feelings
IF SO: Has someone had to actually help you get
things done?
(3) severe: REQUIRES urging, guidance and
reassurance to accomplish regular chores or
personal hygiene
(4) incapacitating: REQUIRES physical
assistance for dress, grooming, eating,
bedside tasks, personal hygiene
23. HOPELESSNESS
In the last week have you felt discouraged or
pessimistic about the future?
HOPELESSNESS:
Do you ever doubt that things will improve? (0) absent
IF YES: How much of the time is this a problem?
Do others try to encourage you? Does it help?
(1) intermittently doubts that things will
improve but can be reassured
(2) more generally feels hopeless but accepts
reassurance
(3) expresses feelings of discouragement,
despair, pessimism about future, which
cannot be dispelled by reassurance
(4) spontaneously and inappropriately
perseverates, "I'll never get well" or the
like.Nihilistic delusions
92
APPENDIX A, continued
24. WORTHLESSNESS
In the past week, what has your opinion of yourself,
compared to others, been like?
WORTHLESSNESS:
(0) absent
Have you felt that you aren't as good as most other
people?
(1) Indicates mild feelings of worthlessness
(low self-esteem) e.g., a little down on
himself
IF YES: How much of the time have you felt like
this?
(2) moderate: Indicates moderate feelings of
worthlessness (loss of self-esteem) e.g.,
feels very bad about himself
Have you felt completely worthless? (3) marked: Different from (2) by degree:
patient feels that he is "no good," "inferior,"
etc., or describes himself as worthless.
(4) severe: Delusional notions of worthlessness
(e.g., "I am a heap of garbage" or its
equivalent)
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HAMILTON RATING SCALE FOR ANXIETY (HRSA)
CIRCLE the answer to each question that best describes how the subject has been feeling
over the PAST WEEK.
None Mild Moderate Severe Very Severe
1. ANXIOUS MOOD 0 1 2 3 4
(Worries, anticipation of the worst,
fearful anticipation, irritability.)
2. TENSION 0 1 2 3 4
(Feelings of tension, fatigability,
startle response, moved to tears easily,
trembling, feelings of restlessness,
inability to relax.)
3. FEARS 0 1 2 3 4
(Of the dark, strangers, being left alone,
animals, traffic, crowds.)
4. INSOMNIA 0 1 2 3 4
(Difficulty in falling asleep, broken
sleep, unsatisfying sleep, fatigue on
waking, dreams, nightmares, night terrors.)
5. INTELLECTUAL (COGNITIVE) 0 1 2 3 4
(Difficulty in concentration, poor memory.)
6. DEPRESSED MOOD 0 1 2 3 4
(Loss of interest, lack of pleasure
in hobbies, depression, early waking,
diurnal swing.)
7. SOMATIC (MUSCULAR) 0 1 2 3 4
(Pains and aches, twitchings,
stiffness, myoclonic jerks, grinding
of teeth, unsteady voice, increased
muscular tone.)
8. SOMATIC (SENSORY) 0 1 2 3 4
(Tinnitus, blurring of vision,
hot and cold flushes, feelings of
weakness, prickling sensation.)
9. CARDIOVASCULAR SYMPTOMS 0 1 2 3 4
(Tachycardia, palpitations,
pain in chest, throbbing of vessels,
fainting feelings, missing beats.)
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None Mild Moderate Severe Very Severe
10. RESPIRATORY SYMPTOMS 0 1 2 3 4
(Pressure of constriction in chest,
choking feelings, sighing, dyspnea.)
11. GASTROINTESTINAL SYMPTOMS 0 1 2 3 4
(Difficulty in swallowing,
passing gas, abdominal pain,
burning sensations, abdominal
fullness, nausea, vomiting,
borborygmus, looseness of
bowels, loss of weight,
constipation.)
12. GENITOURINARY SYMPTOMS 0 1 2 3 4
(Frequency of micturition,
urgency of micturition,
amenorrhea, menorrhagia,
development of frigidity,
premature ejaculation,
loss of libido, impotence.)
13. AUTONOMIC SYMPTOMS 0 1 2 3 4
(Dry mouth, flushing,
pallor, tendency to sweat,
giddiness, tension, headache,
raising of hair on arms
or legs, goose bumps.)
14. BEHAVIOR AT INTERVIEW 0 1 2 3 4
(Fidgeting, restlessness
or pacing, tremor of hands,
furrowed brow, strained
face, sighing or rapid
respiration, facial pallor,
swallowing, belching,
brisk tendon jerks, dilated
pupils, exophthalmos.)
TOTAL_____________
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BECK DEPRESSION INVENTORY - II (BDI-II)
Please read each group of statements carefully, then pick out the one statement in each group
which best describes the way you have been feeling during the past week, including today.
Circle the number beside the statement you have picked. If several statements in the group seem
to apply equally well, simply circle the statement which has the largest number. Be sure that you
do not circle more than one statement for Item 16 (change in sleeping pattern) and Item 18
(change in appetite.)
1 Sadness
0 I do not feel sad.
1 I feel sad much of the time.
2 I am sad all the time.
3 I am so sad or unhappy that I can't stand
it.
2 Pessimism
0 I am not discouraged about my future.
1 I feel more discouraged about my
future than I used to be.
2 I do not expect things to work out for
me.
3 I feel my future is hopeless and will
only get worse.
3 Past Failure
0 I do not feel like a failure.
1 I have failed more than I should have.
2 As I look back, I see a lot of failures.
3 I feel I am a total failure as a person.
4 Loss of Pleasure
0 I get as much pleasure as I ever did
from the things I enjoy.
1 I don't enjoy things as much as I used
to.
2 I get very little pleasure from the things
I used to enjoy.
3 I can’t get any pleasure from the things
I used to enjoy.
5 Guilty Feelings
0 I don't feel particularly guilty.
1 I feel guilty over many things I have
done or should have done.
2 I feel quite guilty most of the time.
3 I feel guilty all of the time.
6 Punishment Feelings
0 I don't feel I am being punished.
1 I feel I may be punished.
2 I expect to be punished.
3 I feel I am being punished.
7 Self Dislike
0 I feel the same about myself as ever.
1 I have lost confidence in myself.
2 I am disappointed in myself.
3 I dislike myself.
8 Self Criticalness
0 I don't criticize or blame myself more
than usual.
1 I am more critical of myself than I used
to be.
2 I criticize myself for all of my faults.
3 I blame myself for everything bad that
happens.
9 Suicidal Thoughts or Wishes
0 I don't have any thoughts of killing
myself.
1 I have thoughts of killing myself, but I
would not carry them out.
2 I would like to kill myself.
3 I would kill myself if I had the chance.
10 Crying
0 I don't cry any more than I used to.
1 I cry more than I used to.
2 I cry over every little thing.
3 I feel like crying but I can’t.
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11 Agitation
0 I am no more restless or wound up than
usual.
1 I feel more restless or wound up than
usual.
2 I am so restless or agitated that it’s hard
to stay still.
3 I am so restless or agitated I have to
keep moving or doing something.
12 Loss of Interest
0 I have not lost interest in other people
or activities.
1 I am less interested in other people or
things than before.
2 I have lost most of my interest in other
people or things.
3 It’s hard to get interested in anything.
13 Indecisiveness
0 I make decisions about as well as ever.
1 I find it more difficult to make
decisions than usual.
2 I have much greater difficulty in
making decisions than I used to.
3 I have trouble making any decisions.
14 Worthlessness
0 I do not feel I am worthless.
1 I don’t consider myself as worthwhile
or useful as I used to.
2 I feel more worthless as compared to
other people.
3 I feel utterly worthless.
15 Loss of Energy
0 I have as much energy as ever.
1 I have less energy than I used to have.
2 I don’t have enough energy to do very
much.
3 I don’t have enough energy to do
anything.
16 Change in Sleeping Pattern
0 I have not experienced any change in
my sleeping pattern.
_______________________________________________________________________
1a I sleep somewhat more than usual.
1b I sleep somewhat less than usual.
_______________________________________________________________________
2a I sleep a lot more than usual.
2b I sleep a lot less than usual.
3a I sleep most of the day.
3b I wake up 1-2 hours early and can’t get
back to sleep.
17 Irritability
0 I am no more irritable than usual.
1 I am more irritable than usual.
2 I am much more irritable than usual.
3 I am irritable all the time.
18 Change in Appetite
0 I have not experienced any change in
my appetite.
_______________________________________________________________________
_
1a My appetite is somewhat less than
usual.
1b My appetite is somewhat greater that
usual.
_______________________________________________________________________
_
2a My appetite is much less than before.
2b My appetite is much greater than usual.
_______________________________________________________________________
_
3a I have no appetite at all.
3b I crave food all the time.
19 Concentration Difficulty
0 I can concentrate as well as ever.
1 I can’t concentrate as well as usual.
2 It’s hard to keep my mind on anything
for very long.
3 I find I can’t concentrate on anything.
20 Tiredness or Fatigue
0 I am no more tired or fatigued than
usual.
1 I get more tired or fatigued more easily
than usual.
2 I am too tired or fatigued to do a lot of
things I used to do.
3 I am too tired or fatigued to do most of
the things I used to do.
21 Loss of Interest in Sex
0 I have not noticed any recent change in
my interest in sex.
1 I am less interested in sex than I used to
be.
2 I am much less interested in sex now.
3 I have lost interest in sex completely.
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BECK ANXIETY INVENTORY (BAI)
Instructions: Please consider each item in the following list of symptoms carefully. Indicate
HOW MUCH you have been bothered by each symptom during the PAST WEEK,
INCLUDING TODAY, by circling the number in the corresponding column for each
symptom.
NONE MILDLY MODERATELY SEVERELY
It did not It did not It was very I could
bother me bother me unpleasant but barely
at all. much. I could stand it. stand it.
1. Numbness or tingling 0 1 2 3
2. Feeling hot 0 1 2 3
3. Wobbliness in legs 0 1 2 3
4. Unable to relax 0 1 2 3
5. Fear of the worst happening 0 1 2 3
6. Dizzy or lightheaded 0 1 2 3
7. Heart pounding or racing 0 1 2 3
8. Unsteady 0 1 2 3
9. Terrified 0 1 2 3
10. Nervous 0 1 2 3
11. Feelings of choking 0 1 2 3
12. Hands trembling 0 1 2 3
13. Shaky 0 1 2 3
14. Fear of losing control 0 1 2 3
15. Difficulty breathing 0 1 2 3
16. Fear of dying 0 1 2 3
17. Scared 0 1 2 3
18. Indigestion or discomfort 0 1 2 3
in abdomen
19. Faint 0 1 2 3
20. Face flushed 0 1 2 3
21. Sweating (not due to heat) 0 1 2 3
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THE POSITIVE AND NEGATIVE AFFECT SCALE
(PANAS, WATSON, CLARK & TELLEGEN, 1988)
PLUS ADDITIONAL ITEMS FROM LARSEN & DIENER (1992)
This scale consists of a number of words that describe different feelings and
emotions. Please indicate to what extent you feel this way RIGHT NOW. Use the
following scale to record your answers.
1 2 3 4 5
very slightly or
not at all
a little moderately quite a bit extremely
1. intense
2. glad
3. hostile NA
4. relaxed
5. surprised
6. proud PA
7. interested PA
8. distressed NA
9. pleased
10. aroused
11. delighted
12. content
13. irritable NA
14. tired
15. miserable
16. ashamed NA
17. drowsy
18. sad
19. excited PA
20. strong PA
21. upset NA
22. still
23. active PA
24. serene
25. bored
26. scared NA
27. happy
28. attentive PA
29. calm
30. inactive
31. sluggish
32. grouchy
33. cheerful
34. at ease
35. enthusiastic PA
36. unhappy
37. stimulated
38. quiet
39. afraid NA
40. gloomy
41. jittery NA
42. dull
43. nervous NA
44. determined PA
45. inspired PA
46. passive
47. tranquil
48. alert PA
49. guilty NA
Note: Original PANAS items are bold; the sub-scales are indicated following the
individual items.
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INSTRUCTIONS FOR THE SORTING TASK
In this sorting task, please assign every item of the attached scales to one of six categories.
The categories are derived from the Mood and Anxiety Symptom Questionnaire (MASQ)
and include:
(1) General Distress: Mixed Symptoms
(2) General Distress: Anxious Symptoms
(3) General Distress: Depressive Symptoms
(4) Somatic Anxiety
(5) Loss of Interest
(6) High Positive Affect
Carefully read the examples of anxiety and depression symptoms for these six categories.
Then, assign each item of the measures HRSD, HRSA, BDI and BAI to the category
which contains symptoms that most closely resemble the item. Many of the items are
almost identical to the example symptoms in the categories, which makes the task fairly
easy. However, be sure to consider all categories before assigning an item. Also, watch
out for reversed key items. Those items may or may not best match with categories
containing their reversed equivalents. For example, the hypothetical items "I ate a lot"
and "I didn't eat a lot" may fit best with two different categories.
If you think an item fits two or more categories equally well, please list all categories. If
an item does not fit any category well, either indicate the category it fits best and write
"poor fit" next to your answer or simply write "0" in the blank next to that item.
Comments are welcome!
Thank you for your help with this.
Sabine
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Category 1: General Distress:
Mixed Symptoms
worried a lot about things
trouble concentrating
felt dissatisfied with things
felt confused
felt irritable
trouble making decisions
trouble paying attention
felt restless
felt something awful would happen
Category 2: General Distress:
Anxious Symptoms
felt tense, "high strung"
felt uneasy
felt nervous
felt afraid
felt "on edge", keyed up
unable to relax
Category 3: General Distress:
Depressive Symptoms
felt depressed
felt discouraged
felt sad
felt hopeless
disappointed in myself
felt like crying
felt like a failure
felt worthless
blamed myself for things
felt inferior to others
pessimistic about the future
felt tired and sluggish
Category 4: Somatic Anxiety
felt dizzy, lightheaded
was trembling, shaking
shaky hands
trouble swallowing
short of breath
dry mouth
twitching or trembling muscles
hot or cold spells
cold or sweaty hands
felt like I was choking
felt faint
pain in chest
racing or pounding heart
felt numbness or tingling
afraid I was going to die
had to urinate frequently
Category 5: Loss of Interest
felt nothing was enjoyable
nothing was interesting or fun
Category 6: High Positive Affect
felt really lively, "up"
felt really happy
felt I had a lot of energy
was having a lot of fun
felt I had much to look forward to
felt good about myself
I had many interesting things to do
felt confident
looked forward to things
felt I had accomplished a lot
was proud of myself
felt cheerful
felt successful
felt optimistic
felt really talkative
moved quickly and easily
felt hopeful about the future
able to laugh easily
felt like being with others
felt very clearheaded
thoughts came to me very easily
felt very alert
could do everything I needed to
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